

AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (July 2003), Supplement 2 (July 2003), Supplement 3 (October 2003), Supplement 4 (November 2003), and Supplement 5 (December 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

- | | | |
|---------------------------|-------------------------------|-------------------------|
| Abbott, K.C., 1058 | Baliga, S., 532 | Burns, A., 582 |
| Abe, K., 76 | Ballanti, P., 1036 | Burns, J.E., 1000 |
| Abraham, M., 797 | Bankhurst, A., 1212 | Byers, P., 229, 1270 |
| Abramson, F., 561 | Barone, G.W., 202 | |
| Abul-Ezz, S.R., 202 | Barré, P.E., 693 | Cai, W., 532 |
| Adachi, M., 1287 | Bartlett, C., 551 | Calabria, S., 1036 |
| Adler, S.G., 395 | Barz, A., 752 | Calonge, V.M., 513 |
| Agodoa, L.Y., 1058 | Baumgarten, D.A., 601 | Campbell, D.A. Jr., 151 |
| Aguilera, A., 787 | Beck, G.J., 44 | Campbell, H., 3:E15 |
| Ahuja, T.S., 376 | Becker, B., 62 | Carmody, S.S., 813 |
| Akiba, T., 303 | Becker, D.J., 117 | Carpenter, B., 1107 |
| Akioka, Y., 1121 | Bedogna, V., 331 | Carrie, B.J., 1020 |
| Alhejaili, F., S1:24 | Bendel, K.J., 3:xlvi | Cass, A., 1043 |
| Al-Hilali, N., 797 | Bennett, W.M., 217 | Castro, M.J., 787 |
| Allen, A.S., 1260 | Benoit, M.O., 513 | Catalano, C., 722 |
| Allon, M., 388, 612 | Bergstralh, E.J., 685 | Catania, A., 143 |
| Al Mousawi, M., 797 | Berns, J.S., 325 | Cattran, D.C., 846 |
| Al-Muzeirei, I.A., 797 | Berto, I.M., 67 | Cauci, F., 3:E11 |
| Alpers, C.E., 605 | Bhattacharia, K.F., 3:E17 | Cavallone, D., 658 |
| Al-Shamari, A., 591 | Bianchin, C., 1177 | Cecka, J.M., 882 |
| Amadori, F., 3:E11 | Bihorac, A., 704 | Celadilla, O., 787 |
| Ambühl, P.M., 193 | Binik, Y.M., 693 | Cernelc, P., 746 |
| Ammann, P., 193 | Blagg, C.R., S1:1 | Cetin, T., 1164 |
| Anderson, P.W., 456 | Blake, P.G., S1:42 | Chalermkulrat, W., 1149 |
| André, J.-L., 5:E19 | Bleyer, A.J., 2:E8 | Chan, L.Y.Y., 173 |
| Andreoni, K., 5:E23 | Blinder, J., 1:xlx | Chan, T.M., 173 |
| Anger, M.S., 315 | Block, G., 864 | Chang, C.-F., 3:E14 |
| Ankenbrandt, M., 926 | Block, S.D., 813 | Chapman, A.B., 1305 |
| Antignac, C., 1:E2 | Boczula, M., 539 | Charbonneau, P., 497 |
| Appel, L.J., 256 | Boero, R., 67 | Charest, A.F., 1193 |
| Arakawa, H., 271 | Bonucci, E., 1036 | Charney, D.A., 1097 |
| Araki, S.-i., 943 | Bosnyak, Z., 117 | Chen, C.-H., 990 |
| Arcidiacono, T., 1177 | Bourgoignie, J.J., 1270, 1293 | Chen, J.-Y., 3:E14 |
| Arnold, R.M., 813 | Bowden, D.W., 133 | Chen, M.L.W., 623 |
| Ars, E., 952 | Brabant, G., 62 | Chen, S.-C., 22 |
| Ascher, N.L., 362 | Brancaccio, D., 143 | Chen, W.-T., 158 |
| Ashizawa, M., 76 | Brancati, F.L., 249, 256 | Chen, Y.-C., 586 |
| Asif, A., 229, 1270, 1293 | Brayman, K., 1000 | Chertow, G.M., 217, 507 |
| Avram, M.M., 864 | Bredi, E., 143 | Cherubini, C., 546 |
| Ayanian, J.Z., 1043 | Brémond-Gignac, D., 5:E19 | Chiang, H.W., 2:E6 |
| Azzi, A., 821 | Brewster, P.S., 926 | Chikamoto, H., 1121 |
| | Briançon, S., 474 | Chiu, Y.S., 2:E6 |
| Badalamenti, S., 143 | Brophy, P.D., 1248 | Cho, D.-K., 2:E7 |
| Badenas, C., 952 | Brown, W.W., 22 | Cho, Y.-J., 2:E7 |
| Bae, K., 2:E7 | Buisson, C., 513 | Chow, K.-M., 5:xlvi |
| Back, H.W., 6:E26 | Bulucu, F., 1164 | Chu, P., 1221 |
| Bagga, A., 1114 | Bunchman, T.E., 1248 | Chua, B.S.Y., 1260 |
| Baggio, E., 331 | Buring, J.E., 234 | Chuang, F.-R., 524 |
| Baines, L.S., 431 | Burket, M.W., 926 | Chung, J.-H., 6:E26 |
| Bajo, M.A., 787 | Burkhart, J., 1082 | Chvala, R., 315 |
| Bakris, G.L., 617, 1301 | Burnett, S., 1184 | Cigni, A., 3:E11 |
| Balducci, A., 1036 | | Clark, W.F., S1:49 |

AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (July 2003), Supplement 2 (July 2003), Supplement 3 (October 2003), Supplement 4 (November 2003), and Supplement 5 (December 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

- | | | |
|---------------------------|-------------------------------|-------------------------|
| Abbott, K.C., 1058 | Baliga, S., 532 | Burns, A., 582 |
| Abe, K., 76 | Ballanti, P., 1036 | Burns, J.E., 1000 |
| Abraham, M., 797 | Bankhurst, A., 1212 | Byers, P., 229, 1270 |
| Abramson, F., 561 | Barone, G.W., 202 | |
| Abul-Ezz, S.R., 202 | Barré, P.E., 693 | Cai, W., 532 |
| Adachi, M., 1287 | Bartlett, C., 551 | Calabria, S., 1036 |
| Adler, S.G., 395 | Barz, A., 752 | Calonge, V.M., 513 |
| Agodoa, L.Y., 1058 | Baumgarten, D.A., 601 | Campbell, D.A. Jr., 151 |
| Aguilera, A., 787 | Beck, G.J., 44 | Campbell, H., 3:E15 |
| Ahuja, T.S., 376 | Becker, B., 62 | Carmody, S.S., 813 |
| Akiba, T., 303 | Becker, D.J., 117 | Carpenter, B., 1107 |
| Akioka, Y., 1121 | Bedogna, V., 331 | Carrie, B.J., 1020 |
| Alhejaili, F., S1:24 | Bendel, K.J., 3:xlvi | Cass, A., 1043 |
| Al-Hilali, N., 797 | Bennett, W.M., 217 | Castro, M.J., 787 |
| Allen, A.S., 1260 | Benoit, M.O., 513 | Catalano, C., 722 |
| Allon, M., 388, 612 | Bergstralh, E.J., 685 | Catania, A., 143 |
| Al Mousawi, M., 797 | Berns, J.S., 325 | Cattran, D.C., 846 |
| Al-Muzeirei, I.A., 797 | Berto, I.M., 67 | Cauci, F., 3:E11 |
| Alpers, C.E., 605 | Bhattacharia, K.F., 3:E17 | Cavallone, D., 658 |
| Al-Shamari, A., 591 | Bianchin, C., 1177 | Cecka, J.M., 882 |
| Amadori, F., 3:E11 | Bihorac, A., 704 | Celadilla, O., 787 |
| Ambühl, P.M., 193 | Binik, Y.M., 693 | Cernelc, P., 746 |
| Ammann, P., 193 | Blagg, C.R., S1:1 | Cetin, T., 1164 |
| Anderson, P.W., 456 | Blake, P.G., S1:42 | Chalermkulrat, W., 1149 |
| André, J.-L., 5:E19 | Bleyer, A.J., 2:E8 | Chan, L.Y.Y., 173 |
| Andreoni, K., 5:E23 | Blinder, J., 1:xlx | Chan, T.M., 173 |
| Anger, M.S., 315 | Block, G., 864 | Chang, C.-F., 3:E14 |
| Ankenbrandt, M., 926 | Block, S.D., 813 | Chapman, A.B., 1305 |
| Antignac, C., 1:E2 | Boczula, M., 539 | Charbonneau, P., 497 |
| Appel, L.J., 256 | Boero, R., 67 | Charest, A.F., 1193 |
| Arakawa, H., 271 | Bonucci, E., 1036 | Charney, D.A., 1097 |
| Araki, S.-i., 943 | Bosnyak, Z., 117 | Chen, C.-H., 990 |
| Arcidiacono, T., 1177 | Bourgoignie, J.J., 1270, 1293 | Chen, J.-Y., 3:E14 |
| Arnold, R.M., 813 | Bowden, D.W., 133 | Chen, M.L.W., 623 |
| Ars, E., 952 | Brabant, G., 62 | Chen, S.-C., 22 |
| Ascher, N.L., 362 | Brancaccio, D., 143 | Chen, W.-T., 158 |
| Ashizawa, M., 76 | Brancati, F.L., 249, 256 | Chen, Y.-C., 586 |
| Asif, A., 229, 1270, 1293 | Brayman, K., 1000 | Chertow, G.M., 217, 507 |
| Avram, M.M., 864 | Bredi, E., 143 | Cherubini, C., 546 |
| Ayanian, J.Z., 1043 | Brémond-Gignac, D., 5:E19 | Chiang, H.W., 2:E6 |
| Azzi, A., 821 | Brewster, P.S., 926 | Chikamoto, H., 1121 |
| | Briançon, S., 474 | Chiu, Y.S., 2:E6 |
| Badalamenti, S., 143 | Brophy, P.D., 1248 | Cho, D.-K., 2:E7 |
| Badenas, C., 952 | Brown, W.W., 22 | Cho, Y.-J., 2:E7 |
| Bae, K., 2:E7 | Buisson, C., 513 | Chow, K.-M., 5:xlvi |
| Back, H.W., 6:E26 | Bulucu, F., 1164 | Chu, P., 1221 |
| Bagga, A., 1114 | Bunchman, T.E., 1248 | Chua, B.S.Y., 1260 |
| Baggio, E., 331 | Buring, J.E., 234 | Chuang, F.-R., 524 |
| Baines, L.S., 431 | Burket, M.W., 926 | Chung, J.-H., 6:E26 |
| Bajo, M.A., 787 | Burkhart, J., 1082 | Chvala, R., 315 |
| Bakris, G.L., 617, 1301 | Burnett, S., 1184 | Cigni, A., 3:E11 |
| Balducci, A., 1036 | | Clark, W.F., S1:49 |

- Clement, L., S1:24, 56
 Codoceo, R., 787
 Coen, G., 1036
 Cohen, L.M., 813
 Cointault, O., 184
 Colamarco, L., 1036
 Colicigno, C.J., 133
 Colindres, R.E., 6:E25
 Collins, A., 22
 Collins, A.J., 972, 1013, 1275
 Colville, D., 2:E3
 Colyer, W.R., 926
 Comandini, U.V., 546
 Como, G., 143
 Comoli, P., 821
 Comozi, F., 4:E18
 Contreras, G., 315
 Cooper, C.J., 926
 Coresh, J., 108, 256, 623
 Counts, C., 12
 Covini, G., 143
 Cozzupoli, P., 722
 Crikis, S., 207
 Critchlow, C.W., 982
 Cunningham, J., 1043
 Curioni, S., 1154
 Cusi, D., 1177
 Cutrupi, S., 722

 D'Agati, V.D., 419
 Dahl, D., 1013
 D'Amico, M., 1154
 Danielski, M., 286
 Danko, H., 713
 Danovitch, G.M., 882
 Darnell, A., 952
 DaRoza, G., 1184
 Das, K.C., 797
 Daubin, C., 497
 Dargirdas, J.T., 1200
 Davies, D.R., 842
 Davison, S.N., 1239
 Dedi, R., 3:E15
 de Ligny, B.H., 4:E18
 DeLong, M.J., 381
 Depner, T.A., S1:42
 de Santis, R., 821
 Devins, G.M., 693
 Di Giulio, S., 546
 Ding, P.Y.-A., 990
 Di Zazzo, G., 1036
 Djurdjev, O., 1184
 Dodd, M., 362
 Dorman, J.S., 117
 Dosekun, A.K., 3:E13
 Drey, N., 677
 Drukker, A., 1107
 du Cheyron, D., 497
 Durand, D., 184

 Easow, S., 797
 Easterling, T.R., 982
 Ebben, J., 972
 Ebben, J.P., 1013
 Eberhardt, M.S., 249, 256
 Eknayan, G., 617
 Ellekjaer, H., 466
 El Menyawi, I., 310
 Elzinga, L., 315
 Emont, S.L., 713
 Endou, H., 1287
 Erlinger, T.P., 256
 Espinoza, M., 787

 Faedda, R., 3:E11
 Falk, R.J., 1149
 Farres, M.T., 1:E2
 Feber, J., 1107
 Fehr, T., 193
 Feldman, H.I., 1000
 Felicioni, R., 546
 Feng, L., 575
 Ferguson, E., S1:56
 Fernandez, J.S., 446
 Ferrando, A., 1212
 Ferrario, F., 1154
 Filler, G., 1107
 Fink, N.E., 108
 Finkelstein, F.O., 350
 Finn, L.S., 1318
 Finn, W.F., 96
 Firpo, M., 331
 Fischer, M.S., 1036
 Flack, J.M., 22
 Fliser, D., 62
 Fochesato, E., 1177
 Fogazzi, G.B., 1154
 Fogo, A.B., 87, 2:xli, 826
 Fontana, I., 821
 Franke, J., 936
 Frankenfield, D.L., 806
 Franssila, K., 960
 Frederick, P.R., 806
 Freedman, B.L., 133
 Freitas, T., 1020
 Friedman, E.A., 2:E4
 Frimat, L., 474
 Froio, N., 546
 Frye, R.F., 906
 Fuchinoue, S., 739
 Fuhrmann, V., 310
 Fujimoto, S.-i., 5:E20
 Fukazawa, A., 1121
 Fumeron, C., 513
 Funovics, M., 539
 Furusu, A., 76

 Gadalean, F., 1270
 Gadallah, M.F., 1270
 Gammara, L., 331
 Gansevoort, R.T., 3:xlvi

 García, J., 53, 264
 García, P., 787
 Garg, J., 1301
 Gaziano, J.M., 234
 Geier, P., 1107
 Gerstein, H.C., 936
 Ghaddar, S., 325
 Ghali, W.A., 125
 Ghoneim, M.A., 370
 Giaculli, F., 108
 Giambona, S., 1177
 Gibney, E.M., 1
 Gilbertson, D., 1275
 Gillen, D.L., 982
 Ginevri, F., 821
 Glynn, R.J., 234
 Goga, T., 2:E10
 Gohdes, D., 245
 Gökden, N., 202
 Goldberg, T., 532
 Goldfarb, D.S., 1
 Goldstein, M.B., 1193
 Goodman, D.G., 207
 Gorban-Brennan, N., 350
 Gorry, M.C., 2:E8
 Gotch, F., 167
 Gotoh, T., 5:E20
 Graf, S., 62
 Grand'Maison, A., 1193
 Grantham, J.J., 427
 Graziani, G., 143
 Greenbaum, L.A., 5:E22
 Greene, T., 44, 1200
 Griffith, T.F., 1260
 Grönghagen-Riska, C., 1139
 Groundstroem, K., 277
 Grüter, E., 193
 Gurley, B.J., 202
 Guymer, R., 2:E3
 Gyamlani, G.G., 685

 Haddad, E., 5:E19
 Hallan, H., 466
 Haller, H., 62
 Hamaoka, K., 5:E20
 Hamburger, R.J., 342
 Haneda, M., 943
 Harada, T., 76
 Hare, J.M., 891
 Hari, P., 1114
 Hart, T.C., 2:E8
 Hartley, B., 3:E15
 Harwell, T.S., 245
 Hattori, M., 1121
 Hayashi, F., 3:E12
 Hebert, L., 617
 Hector, L., 362
 Heidenheim, A.P., S1:5, 24, 30, 36,
 42, 49, 56, 61
 Heinze, G., 539
 Heiro, M., 960

- Helgerson, S.D., 245
 Hemmelfarb, B.R., 125
 Henke, D.C., 1149
 Henke, P., 151
 Hennekens, C.H., 234
 Hibi, I., 295
 Higami, Y., 1:E1
 Hiki, Y., 486
 Hill, P., 842
 Hill, P.A., 207
 Himmelfarb, J., 286, 507
 Hirakawa, S., 133
 Hishida, A., 2:E10, 3:E16
 Ho, S.K.N., 173
 Ho, Y.W., 5:E21
 Hoenich, N.A., 167
 Hogan, S.L., 1149
 Holley, J.L., 813
 Holmen, J., 466
 Honkanen, E., 1139
 Hoofnagle, J.H., 631
 Hoogwerf, B.J., 936
 Horie, A., 486
 Horn, R.G., 87
 Hosoyamada, M., 1287
 Hostetter, T., 617
 Hostetter, T.H., 392
 Houillier, P., 497
 Hsu, C.-y., 623
 Hsu, T.-L., 990
 Hsu, Y.-J., 774
 Huang, C.-C., 524
 Huang, C.Y., 2:E6
 Huang, W.H., 158
 Huhtala, H., 277
 Hung, Y.-J., 774
 Hurtado, A., 575
 Hutchison, F., 12

 Ibrahim, H.N., 1275
 Ihm, C.G., 6:E26
 Ikegaya, N., 295
 Ikizler, T.A., 286, 507, 864
 Ilamathi, M.E., 419
 Iliou, M.C., 513
 Inou, T., 729
 Irjala, K., 36
 Ishani, A., 1275
 Isoaho, R., 36
 Isomoto, H., 76
 Isozaki, T., 3:E16
 Ito, K., 1121
 Itoh, K., 1287
 Iwase, H., 486
 Iyoda, M., 3:E12
 Izopet, J., 184

 Jacob, L., 1:E2
 Jacquot, C., 513
 Jeon, K., 2:E7
 Jindal, R.M., 431

 Joffe, M., 1000
 Johnson, A., 561
 Johnson, R.J., 575
 Johny, K.V., 797
 Jones, S.A., 752
 Jordan, S.C., 1114
 Joseph, J.T., 431
 Joy, M.S., 96

 Kabaya, T., 303
 Kaehny, W.D., 2:E5
 Kaizu, Y., 295
 Kalantar-Zadeh, K., 761, 864
 Kamar, N., 184
 Kane, J.C., 286
 Kanetake, H., 1:E1
 Kao, J.-T., 3:E14
 Kao, W.-Y., 158
 Karim, M., 842
 Kashiwagi, A., 943
 Kato, A., 2:E10
 Kato, M., 486
 Kausz, A.T., 972
 Kawaguchi, H., 1121
 Kawakatsu, H., 5:E20
 Kawasaki, Y., 1131
 Kawashima, A., 303
 Kayler, L.K., 151
 Kays, M.B., 342, 1253
 Kaysen, G., 167
 Kaysen, G.A., 1200
 Keane, W.F., 22
 Kempston, C., 1184
 Kennedy, D.J., 926
 Kessler, M., 474
 Kestenbaum, B., 982
 Khono, M., 1121
 Khuder, S.A., 926
 Kiaii, M., 1184
 Kielstein, J.T., 62
 Kim, M.J., 6:E26
 Kim, Y.-L., 2:E7
 Kimmel, P.L., 713, 1200
 King, K., 22
 Kiser, R.L., 5:E23
 Kissner, P.Z., 6:E24
 Kitamura, K., 1287
 Kitazawa, K., 3:E12
 Kivelä, S.-L., 36
 Kjellstrand, C., 1020
 Klag, M.J., 22, 108
 Klarenbach, S., S1:18
 Klassen, P.S., 1260
 Klemmer, P.J., 1149, 5:E23
 Kliger, A.S., 350
 Knauss, J., 1000
 Kobayashi, Y., 271, 486
 Koç, M., 704
 Kocar, I.H., 1164
 Koga, S., 1:E1
 Kohno, S., 76

 Koji, T., 76
 Kolon, T., 1:xlx
 Kopple, J.D., 761, 864
 Kortas, C., S1:5, 13, 24, 61, 66
 Koskinen, P., 1139
 Kovarik, J., 539
 Kowalewska, J., 605
 Koya, D., 943
 Kroeker, A., S1:49
 Kuenzig, L., S1:49
 Kumagai, H., 295
 Kuo, S.-W., 774
 Kurella, M., 217
 Kuroki, A., 3:E12
 Kurt, I., 1164
 Kurth, T., 234
 Kusek, J.W., 44
 Kvenild, K., 466
 Kwan, B.C.-H., 1069

 Laboi, P., 3:E15
 Lai, K.-B., 781
 Lai, K.N., 173
 Lanfranco, G., 67
 Lange, E.M., 133
 Lapeyraque, A.-L., 5:E19
 Larson, T.S., 685
 Leavey, S., 151
 Lecchi, P., 561
 Leclercq, B., 1270, 1293
 Lee, G.H., 761
 Lee, J., 315
 Lee, S., 1169
 Lee, S.H., 6:E26
 Lee, T.W., 6:E26
 Le Goas, F., 1:E2
 Lehn, R.S., 761
 Lehtimäki, T., 277
 Leitch, R., S1:5, 24, 49, 56, 61
 Lens, X., 952
 Leskinen, Y., 277
 Leung, C.-B., 567, 1069
 Levey, A.S., 44, 108, 617, 623
 Levi, M., 2:E5
 Levin, A., 591, 1184
 Levin, N.W., 167, 1200
 Lew, S.Q., 561
 Li, F.K., 173
 Li, H.-Y., 586
 Li, P. K.-T., 567, 781, 1069
 Li, P. K.T., 5:xlvi
 Lien, Y.-H.H., 381
 Lifrieri, F., 1036
 Lin, C.-C., 3:E14, 586
 Lin, C.-L., 524
 Lin, S.-H., 586, 774, 1221
 Lin, Y.-F., 158, 774
 Lin, Y.-P., 990
 Linas, S.L., 215
 Lindsay, R.M., S1:56
 Lindley, E.J., 551

- Lindsay, R.M., S1:3, 5, 13, 18, 24, 30,
 36, 42, 49, 61, 66
 Lipari, G., 331
 Little, R.R., 245
 Liu, P.-Y., 315
 Lo, K.-Y., 1075
 Lo, W.K., 173
 Lobbedez, T., 4:E18
 Locatelli, F., 821, 1154
 Loewen, A., 1184
 Loirat, C., 5:E19
 Longenecker, J.C., 108
 Lonn, E.M., 936
 Lorenz, M., 539
 Losurdo, G., 821
 Love, J., 1184
 Lu, K.-C., 1221
 Lu, M., 532
 Lucksiri, A., 342
 Luft, F.C., 1283
 Lunghi, G., 143
 Lynes, L., 362

 Maca, T., 539
 Maccario, R., 821
 Macia, M., 53, 264
 Maeda, K., 486
 Maeda, S., 943
 Maes, B., 4:xli
 Magil, A., 591
 Magnasco, A., 752
 Mak, S.-K., 1075
 Makiishi, T., 943
 Malagolini, N., 658
 Manca, A., 3:E11
 Mange, K.C., 1050
 Mann, J.F.E., 936
 Manni, M., 1036
 Manns, B.J., 125
 Mansueto, G., 331
 Marcovina, S.M., 44, 108
 Marcussen, N., 960
 Marino, C., 722
 Markowitz, G.S., 419
 Mars, R.L., 315
 Martin, J.L., 6:E25
 Martorano, C., 722
 Marx, C., 1283
 Marx, M., 1283
 Maschio, G., 331
 Massara, C., 67
 Matsunaga, A., 1121
 Matsuo, M., 1:E1
 Matsushita, K., 1287
 Mattila, K., 36
 Matzke, G.R., 906
 Maxvold, N.J., 1248
 McAllister, C.J., 761
 McClellan, W.M., 806
 McDougall, J., 1193
 McDowall, J.M., 245

 McMonagle, E., 286
 Mehrabian, S., S1:66
 Mehta, R.L., 507
 Meier, P., 1:E2
 Mendelssohn, D.C., 693
 Menon, V., 44
 Merion, R.M., 151
 Merrill, D., 1270, 1293
 Merszei, J., 575
 Meyers, C.M., 631
 Meyers, K., 1:xlix
 Meyette, M., S1:49
 Migdal, S.D., 6:E24
 Mignogna, G., 1177
 Milà, M., 952
 Minagawa, T., 355
 Mishkin, G.J., 561
 Mishkin, M., 561
 Mitterbauer, C., 539
 Mittermayer, C., 310
 Mix, T.-C. H., 972
 Miyaji, K., 295
 Miyakawa, S., 1121
 Miyazaki, M., 76
 Moatti, N., 513
 Moe, S.M., 1253
 Mohamed, N.A.-H., 370
 Moist, L., S1:13, 18, 36
 Mollura, D.J., 891
 Molony, D.A., 22
 Moore, G.M., 325
 Mora, C., 53, 264
 Morana, G., 331
 Morgan, D., S1:66
 Morikawa, A., 271
 Morris, M.C., 431
 Morrow, J., 286
 Moss, A.H., 713, 813
 Moudgil, A., 1114
 Mougenot, B., 1:E2
 Mueller, B.A., 342, 1253
 Muirhead, N., S1:18, 36, 49
 Mullee, M., 677
 Muros, M., 264
 Murphy, L., 167
 Musabak, U., 1164

 Nakakura, H., 1121
 Nakamura, M., 739
 Nakashima, I., 486
 Nampoory, M.R.N., 797
 Nasr, S.H., 419
 Navarro, J.F., 53, 264
 Nelson, R.G., 245
 Nemeth, A.S., 926
 Nesrallah, G., S1:13, 24
 Newmann, J.M., 713
 Nicastrì, E., 546
 Nigg, L., 193
 Nihei, H., 303
 Nishida, M., 5:E20

 Nishimura, R., 117
 Nissenson, A.R., 325, 761
 Nitta, K., 303
 Nofroni, I., 1036
 Nolan, C.R., 1169
 Nolin, T.D., 906
 Nonoguchi, H., 1287

 Oberbauer, R., 539
 Oda, H., 355
 Odamaki, M., 295
 Odani, H., 486
 Oei, L.S., 2:E9
 Ogawa, Y., 729
 Ogino, D., 1121
 Oguz, Y., 1164
 Ohashi, H., 355
 Ohashi, N., 3:E16
 Ohkawa, S., 295
 Ohkuma, T., 355
 Ohmit, S.E., 22
 Ohno, M., 355
 Ohtani, H., 1:E1
 Oksa, H., 1228
 Oktenli, C., 1164
 Oliveira, A., 787
 O'Neill, W.C., 601
 Ono, T., 5:E20
 Orchard, T.J., 117
 Otsubo, O., 729
 Ouwendyk, M., S1:56
 Overholser, B.R., 1253
 Owen, W.F. Jr., 806
 Ozgurtas, T., 1164
 Ozono, Y., 76

 Paganini, E.P., 507
 Paillard, M., 497
 Painter, P.L., 362
 Paiva, A.M., 787
 Panescu, V., 474
 Pangilinan, A., 167
 Park, S.-H., 2:E7
 Parving, H.-H., 617
 Pascual, M.T., 507
 Pasquali, S., 1154
 Pasternack, A., 1228
 Pastorino, N., 821
 Patel, B., 1324
 Paueksakon, P., 87
 Paul, S.M., 362
 Paulson, W.D., 752
 Penumalee, S., 6:E24
 Peppia, M., 532
 Pereira, B.J.G., 972
 Perfumo, F., 821
 Pergola, P.E., 1169
 Perosa, P., 67
 Peters, K., S1:56
 Peters, R.M., 22
 Petrosillo, N., 546

- Ploin, P.-F., 851
 Plöth, D.W., 12
 Poggioli, J., 497
 Poli, A., 331
 Ponikvar, J.B., 746
 Ponticelli, C., 143
 Popovtzer, M.M., 2:E5
 Postorino, M., 722
 Powe, N.R., 108, 249, 256
 Pozzi, C., 1154
 Pujo, M., 4:E18
 Pulliam, J., 315
 Pupim, L., 286

 Quan, H., 125
 Quarello, F., 67
 Quattrocchio, G., 1154

 Rabb, H., 599, 891
 Raj, D.S.C., 1212
 Ram, S.J., 752
 Ramakers, M., 497
 Ramakumar, S., 381
 Rao, M., S1:18
 Rashkow, A., 936
 Ratheiser, K., 310
 Ray, K., 362
 Reddan, D.N., 1260
 Refaie, A.F., 370
 Reif, M.S., 1149
 Reina, T., 1228
 Renaudineau, E., 4:E18
 Renner, E.L., 193
 Revelo, M.P., 87
 Rexrode, K.M., 234
 Reynolds, J.C., 1058
 Rianthavorn, P., 5:E19
 Ribes, D., 184
 Rich, S.S., 133
 Richardson, D., 551
 Riehle, H.-M., 193
 Riley, D.J., 1169
 Rizk, D., 1305
 Robert, N., 315
 Roberts, I.S.D., 842
 Roderick, P., 677
 Rodriguez-Iturbe, B., 575
 Rogerson, M., 677
 Rollino, C., 67, 1154
 Romundstad, S., 466
 Ronco, C., 167
 Ronco, P., 1:E2
 Rosas, S.E., 1000
 Rostaing, L., 184
 Roth, D., 229, 1270, 1293
 Rubinacci, A., 1177
 Ruutu, M., 1139
 Ryan, H., S1:49
 Rycelynck, J.-P., 4:E18

 Šabovic, M., 746
 Sadaniantz, A., 446
 Sadaniantz, B.T., 446
 Saed, T., 797
 Saha, H., 277
 Sahani, M., 2:E9
 Sakai, H., 76
 Sakai, N., 1131
 Sakai, O., 3:E12
 Sakiewicz, P., 325
 Salant, D.J., 395
 Salobir, B., 746
 Salonen, T., 1228
 Salusky, I.B., 5:E19
 Salvadori, M., 143
 Sánchez, S., 787
 Sandhu, J., 2:E8
 Sandres-Saune, K., 184
 Sanisoglu, S.Y., 1164
 Santacroce, S., 167
 Santopietro, A., 821
 Sardella, D., 1036
 Sarnak, M.J., 44, 596
 Satta, A.E., 3:E11
 Savage, B.R., 507
 Savige, J., 2:E3
 Schenk, P., 310
 Schlaeper, C., S1:66
 Schleicher, R.B., 325
 Schmitt, D., 381
 Schneditz, D., 167
 Schnuelle, P., 385
 Schulman, G.W., 1200
 Schwartz, S.M., 982
 Schwarz, C., 539
 Scott, K.M., 381
 Scott, M.K., 342
 Scudo, P., 722
 Seeff, L.B., 631
 Segagni, S., 1154
 Segal, J.H., 151
 Segal, M.S., 704
 Selgas, R., 787
 Seliger, S.L., 982
 Seligman, P.A., 325
 Selves, J., 184
 Sementa, A., 821
 Serafini-Cessi, F., 658
 Serna, J.H., 3:E13
 Sethi, S., 2:E9
 Shafritz, R., 315
 Shah, H., 1212
 Shah, V.O., 1212
 Shapiro, J.L., 926
 Shappell, S., 87
 Sheashaa, A., 370
 Sheerin, N.S., 3:E17
 Shemin, D., 315
 Shepp, P.H., 12
 Sherif, A.M., 370
 Shiao, M.-S., 3:E14

 Shibata, T., 3:E12
 Shimokawa, I., 1:E1
 Shinozaki, S., 2:E10
 Shiraishi, I., 5:E20
 Sinclair, R.A., 2:E3
 Sintonen, H., 1228
 Skluzacek, P.A., 1169
 Slezak, J.M., 685
 Smith, J.M., 1318
 Snelling, P., 1043
 Sobh, M.A.-K., 370
 Soldati, L., 1177
 Solmone, M., 546
 Soro, G., 3:E11
 Soroko, S., 507
 Sowinski, K.M., 342, 1253
 Spanner, E., S1:30
 St. Peter, W.L., 972
 Stampfer, M.J., 234
 Stassen, P.M., 3:xlvi
 States, L., 1:xl
 Steffes, M.W., 617
 Stehman-Breen, C.O., 631, 982
 Sugarman, J.R., 806
 Sugathan, T.N., 797
 Sugisaki, T., 3:E12
 Sugiura, T., 3:E16
 Sullivan, A.M., 813
 Suri, R., S1:13, 30, 42
 Suzuki, H., 1131
 Suzuki, J., 1131
 Suzuki, M., 271
 Swamy, S., 752
 Symons, J.M., 1318
 Szczech, L.A., 1260
 Szeto, C.-C., 567, 781, 1069
 Szeto, C.Y.-K., 781
 Szezew, R.G., 1169

 Taber, T.E., 315
 Tajima, N., 117
 Takada, N., 355
 Takahashi, H.E., 729
 Takahashi, M., 486
 Takizawa, T., 271
 Tam, M.K., 5:E21
 Tanaka, M., 1287
 Tanda, F., 3:E11
 Tang, A.W.C., 5:E21
 Tang, S., 5:E21
 Tanji, M., 1131
 Tarver-Carr, M.E., 249, 256
 Taylor, C.M., 5:E19
 Taylor, J.G.C., 2:E5
 Taylor, P., 591
 Taylor, P.A., 1184
 Tedla, F.M., 2:E4
 Teitelbaum, I., 1082
 Teppo, A.-M., 1139
 Teraoka, S., 739
 Terranegra, A., 1177

- Tessitore, N., 331
 Textor, S.C., 858
 Thalhammer, F., 310
 Thomas, D., 6:E25
 Thomas, D.B., 5:E23
 Thomas, W.J., 926
 Thompson, B., 582
 Ting, G.O., 1020
 Tokuyama, K., 271
 Tomford, R.C., 605
 Tominaga, Y., 729
 Tomita, K., 1287
 Tomlanovich, S.L., 362
 Tong, G.M.W., 1075
 Törmöth, T., 960, 1139
 Torra, R., 952
 Toth, H.L., 5:E22
 Toto, R., 617
 Toto, R.D., 1200
 Trachtman, H., 2:E8
 Troidle, L., 350
 Tsai, T.J., 2:E6
 Tuppin, P., 513
 Turney, J.H., 3:E15
 Tuttle, K.R., 456

 Uchida, K., 303
 Urata, Y., 5:E20
 Uribarri, J., 532

 Vagelli, G., 67
 Vahlberg, T., 36
 van Baarlen, J., 3:xlvi
 Vandermarliere, A., 4:xli
 van der Woude, F.J., 385

 van Poelgeest, B.E., 3:xlvi
 Vanrenterghem, Y., 4:xli
 van Willebrand, E., 1139
 Vassalotti, J.A., 532
 Vega, B. T., 952
 Vesely, T., 315
 Vezzoli, G., 1177
 Vieira, C.F., 229, 1270
 Virtanen, V., 277
 Vlassara, H., 532

 Wakita, N., 1287
 Walker, A.M., 234
 Wang, A.Y.-M., 1069
 Wang, X., 44
 Wanger, A., 3:E13
 Warnock, D.G., 388
 Wasén, E., 36
 Wasser, W., 1097
 Watanabe, J.-i., 1:E1
 Watnick, S., 350
 Watt, C.-L., 1075
 Webb, M.C., 3:E17
 Weiner, D.E., 596
 Welch, R., S1:49
 Weng, F.L., 1050
 White, S., S1:49
 Will, E.J., 551
 Winearls, C.G., 842
 Wolfe, R., 1212
 Wong, A.K.M., 1075
 Wong, P.-N., 1075
 Wong, T.Y.-H., 567, 781
 Wong, Y., 1075
 Woo, J.C.Y., 173

 Wuerth, D.B., 350

 Xue, J., 972
 Xue, J.L., 1013

 Yajima, A., 729
 Yamamoto, T., 3:E16
 Yan, G., 1200
 Yan, H.-C., 158
 Yang, A.-H., 3:E14, 586
 Yang, C.-W., 524
 Yang, H.-Y., 524
 Yang, W.-C., 3:E14, 586, 990
 Yasuda, Y., 486
 Yenicesu, M., 1164
 Yeung, K., 591
 Yeung, L.-K., 1221
 Yi, Q.-L., 936
 Yıldız, O., 1164
 Yoo, T.-H., 6:E26
 Yoon, K.S., 6:E26
 Young, E., 1107
 Yu, C.-C., 524
 Yu, F.-C., 158
 Yu, W.-C., 990
 Yuan, C.M., 1058
 Yumura, W., 303
 Yusuf, S., 936

 Zager, P.G., 1212
 Zarghamee, S., 1020
 Zhu, F., 167
 Zoccali, C., 722
 Zsom, L., 752
 Zupan, I.P., 746
 Zwillich, C.W., 2:E5

SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (July 2003), Supplement 2 (July 2003), Supplement 3 (October 2003), Supplement 4 (November 2003), and Supplement 5 (December 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

Access, vascular. *See* Vascular access

Access to care

kidney transplantation, late referral to nephrologist and, 1043–1049

socioeconomic status and, 249–255

Accreditation Counsel for Graduate Medical Education, core nephrology curriculum and, 215–216

ACE inhibitors. *See* Angiotensin-converting enzyme inhibitors

Acetaminophen

in end-stage renal disease, 217–228

kidney function changes in healthy men and, 234–244

N-Acetyl-b-glucosaminidase excretion in type 2 diabetes, pentoxifylline effects on, 264–270

Acidosis

caused by starvation and stress, 5:E22

metabolic, S3:129–130

Acquired reactive perforating collagenosis, allopurinol therapy for nondiabetic HD patient, 3:E12

ACR. *See* Albumin-creatinine ratio

Acute coronary syndromes, antithrombotic agents for renal patients and, 446–455

- Acute renal failure (ARF)
 after retrograde pyelography, 2:E6
 cohort study, reasons for nonenrollment in, 507–512
 early, novel urinary markers for, 599–600
 exercise-induced, with familial renal hypouricemia, 1287–1292
 in renal lymphoma, diagnosis by percutaneous kidney biopsy, 960–971
 tubule injury, NHE3 as marker for, 497–506
- Acute tubular necrosis, NHE3 protein as marker for, 497–506
- Adequacy
 of peritoneal dialysis, 1082–1096
 of quotidian hemodialysis, S1:42–48
- ADPKD (autosomal dominant polycystic kidney disease), nephrology core curriculum, 1305–1317
- Adrenocorticotrophic hormone deficiency, presenting with hypercalcemia, 2:E10
- Adult-onset tubulointerstitial nephritis and uveitis, with sacroileitis and EBV infection, 3:E11
- Advanced glycation end products (AGEs)
 circulating in renal failure, dietary glycotoxins and, 532–538
 reduction by on-line hemodiafiltration in long-term hemodialysis, 524–531
- Adynamic bone disease, K/DOQI Clinical Practice Guidelines, S3:125–127
- African Americans
 HIV-positive male, immunotactoid glomerulopathy in, 6:E25
 matrix metalloproteinase 9 gene in ESRD, 133–142
 receipt of renal replacement therapy and, 249–255
- Age
 chronic kidney disease risk and, S4:34–S4:41
 prognosis for LCDD with renal involvement, 1154–1163
 thrombotic microangiopathy after renal transplantation and, 1058–1068
- AGEs. *See* Advanced glycation end products
- AKR1B1 C-106T polymorphism, in diabetic nephropathy, 943–951
- Alarms, for nocturnal hemodialysis monitoring, S1:61–65
- Albumin, serum
 correlation with enPCR and CRP, 1200–1211
 CRP levels chronic kidney disease and, 44–52
 hypoalbuminemia
 chronic kidney disease and, 256–263
 inflammation and oxidative stress in maintenance HD, 286–294
 quality of life in ESRD and, 713–721
 in quotidian hemodialysis, S1:30–35
- Albumin, urinary. *See* Microalbuminuria
- Albumin-creatinine ratio (ACR)
 health status of elderly and, 36–43
 in microalbuminuria testing, 245–248
- Albumin to osmolality ratio, in predicting 24-hour urine albumin excretion in diabetes mellitus, 685–692
- Albuminuria. *See* Microalbuminuria
- Aldose reductase, in Japanese patients with type 2 diabetes, 943–951
- Alkalosis, metabolic hypochloremic, after small bowel transplant rejection-related diarrhea, 1283–1286
- Allergic disease, interleukin-4-related gene polymorphisms and, 271–276
- Allocation algorithm development, for kidney transplantation, 882–890
- Allograft, renal
 dysfunction, dense deposit disease and, 207–211
 HBV and HCV-infected, evaluation of, 193–201
 loss, in BKV-associated interstitial nephritis, retransplantation after, 821–825
 mortality in elderly ESRD patients and, 1013–1019
 multicentric papillary renal carcinoma in, 381–384
 preexisting crescentic glomerulonephritis in, 5:E23
 survival, residual renal function in preemptive kidney transplantation and, 1275–1282
- Allopurinol, for acquired reactive perforating collagenosis in nondiabetic HD patient, 3:E12
- Alport's syndrome
 nephrology core curriculum, 1305–1317
 retransplantation after polyoma BK virus-associated allograft loss, 821–825
- Aluminum, overload and toxicity in CKD
 clinical features and therapeutic considerations, S3:108–116
 treatment algorithm, S3:116–122
- Amino acids
 in CAPD dialysate, long-term study of, 173–183
 in ESRD hemodialysis patients, 1212–1220
- Amphotericin B, for mucormycosis peritonitis during long-term PD, 3:E13
- Amyloidosis, long-term outcome of kidney transplant, 370–375
- Analgesic usage
 in ESRD, 217–228
 kidney function changes in healthy men and, 234–244
 for pain in hemodialysis, 1239–1247
 renal disease in postphenacetin era and, 385–387
- ANCA-positive glomerulonephritis
 associated with minocycline, E9
 recurrence after kidney transplantation, 4:E18
- Anderson-Fabry disease, nephrology core curriculum, 1305–1317
- Anemia
 in chronic kidney disease, KEEP program participants and, S4:49–S4:56
 heme iron polypeptide in HD patients, 325–330
 malnutrition-inflammation complex syndrome in dialysis and, 864–881
 management in quotidian hemodialysis, S1:18–23
 renal tubular dysfunction in β -thalassemia minor, 1164–1168
- Angiotensin-converting enzyme (ACE) inhibitors
 for atherosclerotic renal artery stenosis, 851–857
 with calcium channel blockers for nondiabetic nephropathy, 67–75
 for cardiovascular risk reduction in dialysis patients, 1301–1304
 progression of renal insufficiency in type 2 diabetes mellitus, 936–942
- Animal models of diabetic nephropathy, ruboxistaurin effects in, 456–465

- Annexin-V expression, in ESRD hemodialysis patients, 1212-1220
- Anterior ischemic optic neuropathy, in pediatric chronic peritoneal dialysis, 5:E19
- Antibody titer, natural hepatitis B immunity in long-term HD patients, 1193-1199
- Anticoagulant Citrate Dextrose Solution Formula A with Normocarboxylate, for pediatric CVVH, 1248-1252
- Anticonvulsants, in end-stage renal disease, 217-228
- Antidepressants, in end-stage renal disease, 217-228
- Anti-glomerular basement membrane nephritis
dual pattern of immunofluorescence positivity, 419-426
with periglomerular granulomatous reaction and eosinophilic infiltration, 3:E16
- Antihypertensive drugs
for hypertension treatment in incident HD and PD, 1260-1269
utilization to reduce cardiovascular risk in dialysis patients, 1301-1304
- Antineutrophil cytoplasmic antibodies, plasmapheresis for small-vessel vasculitis diffuse alveolar hemorrhage, 1149-1153
- Antiplatelet drugs, for acute coronary syndromes in renal patients, 446-455
- Antithrombotic agents, for acute coronary syndromes in renal patients, 446-455
- Aortic atherosclerosis, in chronic renal failure, 277-285
- Apheresis
for diffuse alveolar hemorrhage in small-vessel vasculitis, 1149-1153
LDL, for children with steroid-resistant FSGS, 1121-1130
triple- vs. dual-lumen catheters for, 315-324
- Apolipoprotein(a), atherosclerotic cardiovascular disease in dialysis patients and, 108-116
- Apolipoprotein E3/3, in protein glomerulopathy with psoriasis vulgaris, 3:E14
- Apoptosis, in ESRD hemodialysis patients, 1212-1220
- ARF. *See* Acute renal failure
- ARPKD (autosomal recessive polycystic kidney disease), nephrology core curriculum, 1305-1317
- Arteriosclerosis
large-artery, ECF-ICF ratio in HD patients and, 990-999
progression of renal insufficiency in type 2 diabetes mellitus, 936-942
- Arteriovenous fistula (AVF)
creation by nephrologists, 1293-1300
stenosis detection and thrombosis prediction, 331-341
successful maturation, predictors of, 1000-1012
transposed basilic vein, vascular outcome and, 151-157
- Ascorbic acid supplementation, effect on oxidative stress parameters in HD, 158-166
- Aspirin
for acute coronary syndromes in renal patients, 446-455
kidney function changes in healthy men and, 234-244
- Atherosclerosis
carotid, in PD patients, 355-361
in CRF, transesophageal echocardiography of, 277-285
in end-stage renal disease, lipoprotein(a) and, 108-116
malnutrition-inflammation complex syndrome in dialysis and, 864-881
with renal artery stenosis, medical management of, 851-857, 858-863
state of endothelium in hemodialysis, circulating endothelial cells and, 704-712
- Atopy, interleukin-4-related gene polymorphisms and, 271-276
- Atypical pneumonia, severe acute respiratory syndrome in hemodialysis patient, 1069-1074
- Autologous stem cell transplantation, for LCDD with renal involvement, 1154-1163
- Autosomal dominant polycystic kidney disease (ADPKD), nephrology core curriculum, 1305-1317
- Autosomal recessive Alport's syndrome, as collagen type IV disease, 952-959
- Autosomal recessive polycystic kidney disease (ARPKD), nephrology core curriculum, 1305-1317
- AVF. *See* Arteriovenous fistula
- BCAAs (branched-chain amino acids), in ESRD hemodialysis patients, 1212-1220
- BCKAD (branched-chain keto acid dehydrogenase), hemodialysis effects on, 1212-1220
- Benign familial hematuria, as collagen type IV disease, 952-959
- Beta-blockers
for hypertension treatment in incident HD and PD, 1260-1269
utilization to reduce cardiovascular risk in dialysis patients, 1301-1304
- Bicarbonate, albumin and creatinine serum levels in dialysis patients and, 1200-1211
- Bicarbonate replacement fluid, and citrate anticoagulation for pediatric CVVH, 1248-1252
- Bioavailability of ciprofloxacin, effects of calcium acetate and sevelamer on, 1253-1259
- Bioimpedance spectroscopy, of large-artery structure and function in HD, 990-999
- Bisphosphonate, PTH secretion in postmenopausal HD patients with secondary hyperparathyroidism, 1221-1227
- Blindness, anterior ischemic optic neuropathy in pediatric CPD, 5:E19
- Blood loss, anemia management in quotidian HD patients and, S1:18-23
- Blood pressure
anterior ischemic optic neuropathy in pediatric CPD, 5:E19
chronic kidney disease risk and, S4:34-S4:41
elevation. *See* Hypertension
quotidian hemodialysis and, S1:13-17
targeted kidney disease screening and, 22-35
- Blood vessel prosthesis, in vivo validation of glucose pump test for access flow, 752-760
- BMD (bone mineral density), intestinal calcium absorption in hypercalciuric stone-forming women and, 1177-1183
- Body mass index (BMI)
chronic kidney disease risk and, S4:34-S4:41
health status of elderly, cystatin C and, 36-43
KEEP program participants, S4:16-27, S4:28-33
quotidian hemodialysis and, S1:30-35

- in renal transplant recipients, exercise training effects on, 362–369
- serum leptin in renal osteodystrophy and, 1036–1042
- targeted kidney disease screening and, 22–35
- Bone disease**
 - adynamic, S3:125–127
 - assessment in chronic kidney disease, S3:57–62
 - in chronic kidney disease, S3:29–44
 - in kidney transplant recipient, S3:130–140
- Bone histomorphometry, serum leptin in renal osteodystrophy and, 1036–1042**
- Bone marrow stem cells, for renal disease, 891–905**
- Bone marrow transplantation, renal tubular regeneration by bone marrow-derived cells after, 5:E20**
- Bone mineral density (BMD), intestinal calcium absorption in hypercalciuric stone-forming women and, 1177–1183**
- Bone remodeling, after parathyroidectomy for secondary hyperparathyroidism, 729–738**
- Booster vaccination, natural hepatitis B immunity in long-term HD patients, 1193–1199**
- Bowel perforation, from peritoneoscopic PD catheter insertion, 1270–1274**
- Brain injury, starvation ketoacidosis and, 5:E22**
- Branched-chain amino acids (BCAAs), in ESRD hemodialysis patients, 1212–1220**
- Branched-chain keto acid dehydrogenase (BCKAD), hemodialysis effects on, 1212–1220**
- Cadaver kidney allocation, algorithm development for, 882–890**
- Calcineurin inhibitors, thrombotic microangiopathy after renal transplantation and, 1058–1068**
- Calcium**
 - adrenocorticotrophic hormone deficiency in long-term HD and, 2:E10
 - hypocalcemia, in chronic kidney disease, S3:29–44
 - intestinal absorption in idiopathic hypercalciuria, BMD in stone-forming women and, 1177–1183
 - lanthanum carbonate effects on, 96–107
 - metabolism, evaluation of, S3:52–57
 - pamidronate for secondary hyperparathyroidism and, 1221–1227
 - quotidian hemodialysis and, S1:24–29
- Calcium acetate and sevelamer, bioavailability of ciprofloxacin and, 1253–1259**
- Calcium carbonate, vascular calcification in long-term HD and, 303–309**
- Calcium-channel blockers**
 - with ACE inhibitor, for nondiabetic nephropathy, 67–75
 - for hypertension treatment in incident HD and peritoneal dialysis, 1260–1269
- Calcium oxalate, nephrolithiasis in cystic fibrosis and, 1–11**
- Calcium-phosphorus product, K/DOQI Clinical Practice Guidelines, S3:77–84**
- Calcium × phosphate, quotidian hemodialysis and, S1:24–29**
- Canulation, in quotidian hemodialysis, S1:56–60**
- CAPD. *See* Continuous ambulatory peritoneal dialysis**
- Caspase-3, in ESRD hemodialysis patients, 1212–1220**
- Cardiovascular disease**
 - circulating AGEs in renal failure, dietary glycotoxins and, 532–538
 - CRP levels chronic kidney disease and, 44–52
 - in dialysis patients, lipoprotein(a) and, 108–116
 - in ESRD
 - lipoprotein(a) and, 108–116
 - prognostic value of cardiac markers for, 513–523
 - hypertensive pregnancy and, 982–989
 - malnutrition-inflammation complex syndrome in dialysis and, 864–881
 - microalbuminuria as risk marker for, 596–598
 - microalbuminuria testing methods in, 245–248
 - progression of renal insufficiency in type 2 diabetes mellitus, 936–942
 - risk factors
 - in renal transplant patients, exercise training effects on, 362–369
 - vascular calcification in long-term HD and, 303–309
 - special studies, S5:141–150
 - state of endothelium in HD, circulating endothelial cells and, 704–712
- Carotid atherosclerosis, in PD patients, 355–361**
- Case mix, adapting Charlson Comorbidity Index for ESRD, 125–132**
- Cast nephropathy, Tamm-Horsfall glycoprotein and, 658–676**
- Catheter-related infections, triple- vs. dual-lumen catheters and, 315–324**
- Catheters**
 - insertion, in diagnostic and interventional nephrology program, 229–233
 - mortality in elderly ESRD patients and, 1013–1019
 - peritoneal dialysis, 1082–1096
 - triple- vs. dual-lumen for hemodialysis and apheresis, 315–324
- CD68, prognosis of MPGN type I renal dysfunction and, 1131–1138**
- Cell-mediated immunity, effect of hygiene and socioeconomic factors on, 575–581**
- Cellulose acetate high performance-210 hemodialyzer, levofloxacin removal, 342–349**
- CHANCE (Chronic Hemodialysis and New Cardiac Markers Evaluation), prognostic value of cardiac markers in ESRD, 513–523**
- Charlson Comorbidity Index, adapting for use in ESRD, 125–132**
- Chemotherapy, for LCCD with renal involvement, 1154–1163**
- Children**
 - on CPD, anterior ischemic optic neuropathy in, 5:E19
 - CVVH with Normocarb replacement fluid and citrate anticoagulation, 1248–1252
 - in-center hemodialysis, ESRD Clinical Performance Measures Project 2002 Annual Report on, S2:48–56
 - with minimal change nephrotic syndrome, IL-4 gene polymorphisms in, 271–276
 - MPGN type I renal dysfunction prognosis, α -smooth muscle actin and, 1131–1138
 - renal transplant recipients, quality of life for, 431–445

- renal tubular regeneration by bone marrow-derived cells after BMT, 5:E20
- retransplantation after polyoma BK virus-associated allograft loss, 821-825
- severe acidosis caused by starvation and stress, 5:E22
- with steroid-resistant FSGS, prednisone and LDL apheresis for, 1121-1130
- Chloride ion channels, nephrolithiasis in cystic fibrosis and, 1-11
- Chloridorrhea, after small bowel transplant rejection, 1283-1286
- Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study, Lp(a) in atherosclerotic cardiovascular disease, 108-116
- Cholesterol in renal transplant recipients, exercise training effects on, 362-369
- Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE), prognostic value of cardiac markers in ESRD, 513-523
- Chronic kidney disease (CKD)
- analgesia in, 217-228
 - anemia in. *See* Anemia
 - aortic atherosclerosis in, 277-285
 - early detection of, 392-393
 - Healthy People 2010 objectives, S5:25-36
 - hospitalization frequency in, 972-981
 - incidence and outcomes, population-based study of, 677-684
 - K/DOQI Clinical Practice Guidelines. *See* K/DOQI Clinical Practice Guidelines
 - K/DOQI definition of, 623-625, 626-630
 - KEEP program participants, S4:16-27, S4:42-48
 - late referral to nephrologist, access to kidney transplantation and, 1043-1049
 - markers, position statement of NKF and NIDDK, 617-622
 - outcome, impact of nephrology referral on, 474-485
 - receipt of RRT, sociodemographic disparities and, 249-255
 - in renal hyperparathyroidism, percutaneous ethanol injection therapy for, 739-745
 - stage, in predicting seroconversion after HBV vaccination, 1184-1192
 - time to dialysis, predialysis psychoeducational intervention and coping styles, 693-703
 - USRDS annual report on, S5:37-46
- Ciprofloxacin bioavailability, effects of calcium acetate and sevelamer on, 1253-1259
- Circulating endothelial cells, endothelium in hemodialysis patients and, 704-712
- Cirrhosis
- hepatitis C virus and, 631-657
 - prediction of GFR in liver transplant candidates, 1169-1176
- Citrate anticoagulation, with Normocarb replacement fluid for pediatric CVVH, 1248-1252
- CKD. *See* Chronic kidney disease
- Clinical performance measures, developing, based on K/DOQI Clinical Practice Guidelines, 806-812
- Clinical trials. *See* Randomized controlled trials; *specific clinical trials*
- Clopidogrel, for acute coronary syndromes in renal patients, 446-455
- c-met, hereditary papillary renal cell carcinoma in renal allograft, 381-384
- Cochrane Renal Group report, published and ongoing trials, 837-841
- Cockcroft and Gault formula, prediction of GFR in liver transplant candidates, 1169-1176
- Cohort studies of ARF, reasons for nonenrollment in, 507-512
- Collagen type IV gene mutations in Alport's syndrome and benign familial hematuria, 952-959
- Collapsing glomerulopathy, with membranous glomerulonephritis in native kidney biopsies, 591-595
- Color Doppler ultrasound, vs. ultrasound dilution method or fistulography, 539-545
- Congenital nephrotic syndrome, case report of, 1318-1323
- Contamination, by HBV and HCV in dialysis setting, 546-550
- Continuous ambulatory peritoneal dialysis (CAPD)
- in Finland, cost analysis of, 1228-1238
 - long-term study of amino acid dialysate in, 173-183
 - rosiglitazone improvement of glucose metabolism in non-diabetic uremia, 774-780
- Continuous peritoneal dialysis (CPD)
- anterior ischemic optic neuropathy in children and, 5:E19
 - ultrafiltration volume measurement, by segmental bioimpedance analysis, 167-172
- Continuous venovenous hemodialysis (CVVHD), vs. CVVH with Normocarb replacement fluid and citrate anticoagulation for children, 1248-1252
- Continuous venovenous hemofiltration (CVVH)
- with Normocarb replacement fluid and citrate anticoagulation, 1248-1252
 - single-dose ofloxacin pharmacokinetics in, 310-314
- Coping styles, time to dialysis and, 693-703
- Coronary heart disease. *See* Cardiovascular disease
- Coronavirus, severe acute respiratory syndrome in hemodialysis patient, 1069-1074
- Costs
- analysis of renal replacement therapies in Finland, 1228-1238
 - comparison of conventional vs. home quotidian hemodialysis, S1:49-55
 - of dialysis in ESRD, 12-21
- C-reactive protein (CRP)
- albumin and creatinine independent association with, 1200-1211
 - carotid atherosclerosis in PD patients and, 355-361
 - in chronic kidney disease, 44-52
 - effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance HD, 761-773
 - maintenance HD patients with hypoalbuminemia, 286-294
 - muscle mass in long-term hemodialysis and, 295-302
 - urinary albumin excretion in type 2 diabetes mellitus and, 53-61
- Creatinine, serum
- chronic kidney disease incidence and outcomes and, 677-684
 - correlation with enPCR and CPR, 1200-1211

- elevated, kidney disease screening for, 22-35
 prognosis for LCDD with renal involvement, 1154-1163
 progression of renal insufficiency in type 2 diabetes mellitus, 936-942
 vs. serum cystatin C in GFR estimating, 36-43
- Creatinine clearance, prediction of GFR in liver transplant candidates, 1169-1176
- Creatinine kinase, prognostic value in ESRD, 513-523
- Crescentic glomerulonephritis
 ANCA-positive, associated with minocycline, 2:E9
 preexisting in renal allograft, 5:E23
 proteinuria, doxycycline effects on, 366-380
- Cryoglobulinemia
 hepatitis C virus and, 631-657
- Cryptoglobulinemia
 glomerulonephritis of, monoclonal gammopathy deposition and, 87-95
- Crystals, in podocytes, 605-611
- C-106T polymorphism of *AKR1B1*, in diabetic nephropathy, 943-951
- CVVH. *See* Continuous venovenous hemofiltration
- CVVHD, vs. CVVH with Normocarb replacement fluid and citrate anticoagulation for children, 1248-1252
- Cyclophosphamide resistance in minimal change nephrotic syndrome, tacrolimus for, 5:E21
- Cyclosporine, thrombotic microangiopathy after renal transplantation and, 1058-1068
- Cystatin C, in elderly, 36-43
- Cystic fibrosis, nephrolithiasis and, 1-11
- Cystic fibrosis transmembrane conductance regulator, nephrolithiasis in cystic fibrosis and, 1-11
- Cystic kidney diseases, nephrology core curriculum, 1305-1317
- Cytochrome P-450, hepatic drug metabolism in kidney disease and, 906-925
- Cytokines. *See also specific cytokines*
 effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance HD, 761-773
 in ESRD hemodialysis patients, 1212-1220
 in maintenance HD patients with hypoalbuminemia, 286-294
- Daily hemodialysis
 adequacy of, S1:42-48
 anemia management, S1:18-23
 calcium and phosphate balance in, S1:24-29
 conversion to, comorbidity in ESRD and, 1020-1035
 nursing issues, S1:56-60
 nutritional status and, S1:30-35
 operating cost comparisons for, S1:49-55
 patient quality of life, S1:36-41
 technical considerations, S1:66-70
 volume control and blood pressure management in, S1:13-17
- Demographics, receipt of RRT and, 249-255
- Dense deposit disease
 early renal allograft dysfunction and, 207-211
 retinal abnormalities causing visual impairment, 2:E3
- Depression, peritonitis in long-term PD and, 350-354
- Diabetes mellitus
 AVF creation by nephrologists and, 1293-1300
- KEEP program patients, S4:16-27
- microalbuminuria testing methods, 245-248
- rapidly progressive irreversible renal failure with pancreatic insufficiency, 842-845
- state of endothelium in hemodialysis patients, circulating endothelial cells and, 704-712
- targeted kidney disease screening and, 22-35
- type 1, incidence of ESRD and survival after RRT, 117-124
- type 2, progression of renal insufficiency in, 936-942
- urinary albumin to osmolality ratio in predicting 24-hour urine albumin excretion, 685-692
- urinary NAG excretion, pentoxifylline and, 264-270
- Diabetic nephropathy
 C-106T polymorphism of *AKR1B1* and, 943-951
 urinary albumin excretion, inflammatory parameters and, 53-61
 with vascular complications, ruboxistaurin for, 456-465
 in vitro closure time test for hemostasis assessment in, 746-751
- Diagnostic and interventional nephrology program, development of, 229-233
- Dialysate
 amino acid, long-term study in CAPD, 173-183
 calcium concentrations in, S3:98-102
- Dialysis. *See also specific dialysis modalities*
 antihypertensive usage to reduce cardiovascular risk in, 1301-1304
 hepatitis B and C virus contamination, 546-550
 hepatitis C virus-related renal disease and, 631-657
 initiation, transplant evaluation before, 1050-1057
 long-term
 need for end-of-life care training in nephrology, 813-820
 xerostomia and xerophthalmia in end-stage renal disease, 722-728
 malnutrition-inflammation complex syndrome in, 864-881
 selection of modality, 1082-1096
 severe acute respiratory syndrome in, clinical presentation and outcome of, 1075-1081
 solutions, for peritoneal dialysis, 1082-1096
 in vitro closure time test for hemostasis assessment in, 746-751
- Dialysis dose conversion, comorbidity of ESRD patients and, 1020-1035
- Dialysis membrane composition, effect on erythrocyte response, 551-560
- Dialysis prescription, for peritoneal dialysis, 1082-1096
- Diarrhea
 chloridorrhea after small bowel transplant rejection, 1283-1286
 watery, with hyperkalemia, 2:E5
- Dietary glycotoxins, circulating advanced glycation end products in renal failure and, 532-538
- Differentiation, of stem cells for kidney disease, 891-905
- Diffuse alveolar hemorrhage in small-vessel vasculitis, plasmapheresis for, 1149-1153
- Doxorubicin, for LCDD with renal involvement, 1154-1163
- Doxycycline, effect on proteinuria in glomerulonephritis, 366-380

Drugs. *See also specific drugs*

- hepatic metabolism in kidney disease, 906-925
- toxicity, sirolimus-induced thrombotic microangiopathy after renal transplant, 202-206

Economic costs. *See Costs*

Elderly

- analgesia in end-stage renal disease, 217-228
- AVF creation by nephrologists and, 1293-1300
- chronic kidney disease incidence and outcomes and, 677-684
- health status, cystatin C and, 36-43
- survival, dialysis access type in ESRD patients and, 1013-1019

Embryonic stem cell research, ethical and legal issues, 891-905

End-of-life care, training in nephrology, need for, 813-820

Endothelial function, effect of ruboxistaurin in diabetic nephropathy, 456-465

Endothelial NO synthase gene polymorphism with basal peritoneal membrane function in uremia, 781-786

Endothelium, state in hemodialysis patients, circulating endothelial cells and, 704-712

Endovascular procedures, in diagnostic and interventional nephrology program, 229-233

End-stage renal disease (ESRD)

- analgesia in, 217-228
- anemia in. *See Anemia*
- anterior ischemic optic neuropathy in children on chronic peritoneal dialysis, 5:E19
- antihypertensive usage to reduce cardiovascular risk in dialysis patients, 1301-1304
- atherosclerotic cardiovascular disease, in dialysis patients, lipoprotein(a) and, 108-116
- comorbidity
 - Charlson Comorbidity Index prediction of, 125-132
 - conversion from conventional to short daily hemodialysis and, 1020-1035
- depression, peritonitis in long-term PD and, 350-354
- dialysis costs in, 12-21
- economic costs, S5:161-172
- hemodialysis patient with SARS and SLE, 1069-1074
- hospitalization frequency in, 972-981
- hyperphosphatemia, lanthanum carbonate for, 96-107
- hypertension treatment in incident HD and peritoneal dialysis, 1260-1269
- impact of nephrology referral on outcome, 474-485
- incidence, after renal replacement therapy for type 1 diabetes, 117-124
- international comparisons, S5:173-181
- kidney transplantation, S5:115-128
- late referral to nephrologist, access to kidney transplantation and, 1043-1049
- long-term peritoneal dialysis, gabapentin-induced hypoglycemia in, 6:E24
- maintenance hemodialysis, hypercoagulability in, 797-805
- markers of inflammation, proteolysis and apoptosis in, 1212-1220
- need for end-of-life care training in nephrology, 813-820
- outcomes, S5:103-114
- patient characteristics, S5:61-74
- pediatric, S5:129-140
- peginterferon pharmacokinetics in, 631-657
- prevalence and incidence, S5:47-60
- prognostic value of cardiac markers in, 513-523
- reduction of AGEs in long-term HD by on-line hemodiafiltration, 524-531
- rehabilitation and quality of life, S5:151-160
- renal replacement therapies in Finland, cost analysis of, 1228-1238
- socioeconomic status effect on treatment, 249-255
- treatment modalities, S5:75-86
- xerostomia and xerophthalmia in, 722-728

ENOS gene polymorphism, with basal peritoneal membrane function in uremia, 781-786

enPCR (Equilibrated normalized protein catabolic rate), albumin and creatinine independent association with, 1200-1211

Epidemiology

- chronic kidney disease incidence and outcomes, population-based study of, 677-684
- of glomerulonephritis, effect of hygiene and socioeconomic factors, 575-581

Epidémiologie de l'Insuffisance Renale Chronique Terminale en Lorraine (EPIREL), impact of nephrology referral on ESRD outcome, 474-485

EPO. *See Erythropoietin*Epoetin. *See Erythropoietin*

Epstein-Barr virus infection, adult-onset tubulointerstitial nephritis and uveitis and, 3:E11

Equilibrated normalized protein catabolic rate (enPCR), albumin and creatinine independent association with, 1200-1211

Equipment

- hepatitis B and C virus contamination in dialysis, 546-550
- for quotidian hemodialysis, S1:66-70

Erythrocyte aldose reductase, in Japanese patients with type 2 diabetes, 943-951

Erythropoiesis, hemodialysis membrane composition effect on erythrocyte response, 551-560

Erythropoietin (EPO). *See also Recombinant human erythropoietin*

- anemia management in quotidian hemodialysis, S1:18-23
- biocompatibility, hemodialysis membrane composition effect on erythrocyte response, 551-560
- EPO-producing gastric carcinoma, in hemodialysis patient, 1:E1
- heme iron polypeptide in HD patients and, 325-330
- malnutrition-inflammation complex syndrome in dialysis and, 864-881

Escherichia coli, Tamm-Horsfall glycoprotein excretion and, 658-676

ESRD. *See End-stage renal disease*

ESRD Clinical Performance Measures Project 2002 Annual Report

- adult in-center HD patients, S2:19-38
- adult peritoneal dialysis, S2:39-48
- background and project methods, S2:11-18
- executive summary, S2:4-10
- pediatric in-center hemodialysis, S2:48-56

- Estimated glomerular filtration rate, kidney disease screening, 22–35
- Ethanol injection therapy, for HD patients with renal hyperparathyroidism, 739–745
- Ethics
organ allocation for kidney transplantation, 882–890
of stem cell therapy for renal disease, 891–905
- Ethnicity
chronic kidney disease risk, KEEP program participants and, S4:34–S4:41
quality of life in ESRD and, 713–721
- Exercise training effects, on coronary risk factors in renal transplant patients, 362–369
- Exocrine pancreatic insufficiency, in peritoneal dialysis patients, 787–796
- Extracellular fluid volume
quotidian hemodialysis and, S1:13–17
ratio to intracellular fluid, large-artery derangement in HD and, 990–999
- Familial juvenile hyperuricemic nephropathy, Tamm-Horsfall glycoprotein and, 658–676
- Familial renal hypouricemia, with exercise-induced ARF, 1287–1292
- Ferritin, serum
heme iron polypeptide in HD patients and, 325–330
in vitro oxidative effects of ascorbic acid in uremia and, 158–166
- Finland, cost analysis of renal replacement therapies in, 1228–1238
- Fistula, mortality in elderly ESRD patients and, 1013–1019
- Fistulography, vs. color Doppler ultrasound or ultrasound dilution method, 539–545
- Flushing, cyclosporine-induced in minimal change nephrotic syndrome, 5:E21
- Focal segmental glomerulonephritis, idiopathic, with membranous glomerulonephritis in native kidney biopsies, 591–595
- Focal segmental glomerulosclerosis (FSGS)
and hyalinosis with lymphoproliferative disorders, 1097–1101
incidence in children, 1107–1113
steroid-dependent, mycophenolate mofetil and prednisolone for, 1114–1120
steroid-resistant, prednisone and LDL apheresis for, 1121–1130
- Follow-up study, of healthy subjects with microalbuminuria, all-cause mortality and, 466–473
- FSGS. *See* Focal segmental glomerulosclerosis
- Furosemide, for Gitelman's syndrome with Sjogren's syndrome, 586–590
- Gabapentin-induced hypoglycemia, in long-term peritoneal dialysis patient, 6:E24
- Gastric carcinoma, EPO-producing in hemodialysis patient, 1:E1
- Gastrointestinal dysfunction, in peritoneal dialysis patients, 787–796
- Gender
chronic kidney disease risk and, S4:34–S4:41
quality of life in ESRD and, 713–721
- Gene polymorphisms
in children with minimal change nephrotic syndrome, 271–276
ENOS, with basal peritoneal membrane function in uremia, 781–786
- Genetic association, matrix metalloproteinase 9 gene in ESRD, 133–142
- GFR. *See* Glomerular filtration rate
- Gitelman's syndrome
NCCT gene mutations in Korean patient, 6:E26
with Sjogren's syndrome presenting with muscular paralysis, 586–590
- Glomerular filtration rate (GFR)
analgesia in healthy men and, 234–244
chronic kidney disease and, S4:42–S4:48
C-reactive protein levels chronic kidney disease and, 44–52
in elderly, cystatin C as marker for, 36–43
estimated, for kidney disease screening, 22–35
position statement of NKF and NIDDK, 617–622
prediction in liver transplant candidates, 1169–1176
resistin blood levels in renal disease and, 62–66
- Glomerulonephritis. *See also* Crescentic glomerulonephritis; Membranoproliferative glomerulonephritis
AGBM antibody-induced, with periglomerular granulomatous reaction and eosinophilic infiltration, 3:E16
ANCA-positive, recurrence after kidney transplantation, 4:E18
hepatitis C virus and, 631–657
hygiene hypothesis of, 575–581
proteinuria, doxycycline effects on, 366–380
- Glucocorticoids, cystatin C increase in elderly and, 36–43
- Glucose, starvation ketoacidosis and, 5:E22
- Glucose pump tests, for access flow measurement, in vivo validation of, 752–760
- Glucose tolerance, rosiglitazone effect in nondiabetic uremic patients on CAPD, 774–780
- Glycosyl phosphatidylinositol anchored proteins, Tamm-Horsfall glycoprotein excretion and, 658–676
- Goodpasture's syndrome, dual pattern of immunofluorescence positivity, 419–426
- Growth factor urinary excretion, MGN clinical course and, 1139–1148
- Haplotype, erythrocyte aldose reductase in type 2 diabetes and, 943–951
- HBV. *See* Hepatitis B virus
- HCV. *See* Hepatitis C virus
- HD. *See* Hemodialysis
- HDL in renal transplant recipients, exercise training effects on, 362–369
- Health care resources, utilization in advancing chronic kidney disease, 972–981
- Health insurance, access to care and, 249–255
- Health-related quality of life. *See* Quality of life
- Health Utilities Index, quality of life on quotidian hemodialysis, S1:36–41
- Healthy People 2010, chronic kidney disease objectives, S5:25–36
- Heart Outcomes and Prevention Evaluation (HOPE), results of, 936–942

- Hematocrit, heme iron polypeptide in HD patients and, 325-330
- Hematuria, targeted kidney disease screening and, 22-35
- Heme iron polypeptide, as replacement of IV iron therapy in HD patients, 325-330
- Hemodialfiltration, on-line, reduction of AGEs in long-term HD, 524-531
- Hemodialysis (HD)
- access. *See* Vascular access
 - acquired reactive perforating collagenosis, allopurinol for, 3:E12
 - ascorbic acid effect on in vitro oxidative stress parameters, 158-166
 - conventional, conversion to daily HD, comorbidity in ESRD and, 1020-1035
 - cost analysis in Finland, 1228-1238
 - daily. *See* Daily hemodialysis
 - effects of CRP, enPCR and serum bicarbonate on creatinine and albumin levels, 1200-1211
 - effects on ubiquitin-proteasome and BCKAD pathways, 1212-1220
 - EPO-producing gastric carcinoma in, 1:E1
 - in ESRD, costs of, 12-21
 - for HCV-positive patients, effect on viremia and IFN- α levels, 143-150
 - home
 - patient monitoring, S1:61-65
 - technical considerations, S1:66-70
 - hypertension treatment in, 1260-1269
 - in-center, ESRD Clinical Performance Measures Project 2002 Annual Report on
 - adult, S2:19-38
 - pediatric, S2:48-56
 - initial access type, mortality outcomes in elderly ESRD patients, 1013-1019
 - large-artery derangement in, ECF-ICF ratio and, 990-999
 - levofloxacin clearance in ESRD, 342-349
 - long-term
 - adrenocorticotrophic hormone deficiency presenting with hypercalcemia in, 2:E10
 - vascular calcification, serum osteoprotegerin and, 303-309
 - maintenance
 - in ESRD, hypercoagulability and, 797-805
 - hypoalbuminemia linked with inflammation and oxidative stress in, 286-294
 - morbidity/mortality, S1:5-12
 - nocturnal. *See* Nocturnal hemodialysis
 - outcome
 - impact of nephrology referral for ESRD, 474-485
 - transposed basilic vein arteriovenous fistula and, 151-157
 - pain, 1239-1247
 - predictors of successful AVF maturation, 1000-1012
 - prognostic value of cardiac markers in ESRD, 513-523
 - PTH secretion in postmenopausal women with secondary hyperparathyroidism, pamidronate effects on, 1221-1227
 - quality of life in ESRD, symptoms, spiritual beliefs, psychosocial factors and ethnicity, 713-721
 - quotidian, S1:5-12
 - renal osteodystrophy, serum leptin in, 1036-1042
 - severe acute respiratory syndrome in, 1069-1074
 - state of endothelium, circulating endothelial cells and, 704-712
 - triple- vs. dual-lumen catheters for, 315-324
 - ultrasound dilution access blood flow for AVFs, 331-341
 - in vitro closure time test for hemostasis assessment in, 746-751
- Hemodialysis membrane, in vitro performance after repeated processing, 561-566
- Hemoglobin
- hemodialysis membrane composition effect on erythrocyte response, 551-560
 - quality of life in ESRD and, 713-721
 - targeted kidney disease screening and, 22-35
- Hemolytic uremic syndrome, thrombotic microangiopathy after renal transplantation and, 1058-1068
- Heparin, for acute coronary syndromes in renal patients, 446-455
- Hepatitis B surface antigen, contamination in dialysis setting, 546-550
- Hepatitis B virus (HBV)
- contamination dialysis setting, 546-550
 - evaluation in renal allograft recipients, 193-201
 - natural immunity in long-term HD patients, 1193-1199
 - vaccination before dialysis, stage of CKD in predicting seroconversion, 1184-1192
- Hepatitis C virus (HCV)
- contamination dialysis setting, 546-550
 - effect of hemodialysis on viremia and IFN- α levels, 143-150
 - evaluation in renal allograft recipients, 193-201
 - long-term ribavirin therapy for renal transplant patients, 184-192
 - renal disease and, 631-657
- Hereditary nephritis, nephrology core curriculum, 1305-1317
- Hereditary papillary renal cell carcinoma, in renal allograft, 381-384
- High-density lipoprotein in renal transplant recipients, exercise training effects on, 362-369
- Hinge glycopeptides, in IgA nephrology, 486-496
- HIV-associated nephropathy, in African-American male, 6:E25
- Home hemodialysis
- patient monitoring, S1:61-65
 - technical considerations, S1:66-70
- Homocysteine
- carotid atherosclerosis in PD patients and, 355-361
 - quotidian hemodialysis and, S1:13-17
- HOPE (Heart Outcomes and Prevention Evaluation), results of, 936-942
- Hospitalization
- during advancing chronic kidney disease, 972-981
 - ESRD, USRDS annual report on, S5:103-114
- Hospital resource utilization, dialysis costs in ESRD and, 12-21
- Human leukocyte antibodies, organ allocation for kidney transplantation, 882-890
- Hyaluronate, evaluation of HBV- and HCV-infected renal allografts, 193-201

- Hygiene hypothesis, of glomerulonephritis, 575-581
- Hypercalcemia, adrenocorticotrophic hormone deficiency in long-term HD, 2:E10
- Hypercalciuria, idiopathic, intestinal calcium absorption-bone mineral density relationship in stone-forming women, 1177-1183
- Hypercholesterolemia, aortic atherosclerosis in chronic renal failure, 277-285
- Hypercoagulability, in ESRD patients on maintenance hemodialysis, 797-805
- Hyperglycemia, effect of protein kinase C β inhibition on, 456-465
- Hyperinsulinemia, gabapentin-induced hypoglycemia in long-term peritoneal dialysis, 6:E24
- Hyperkalemia, with concomitant watery diarrhea, 2:E5
- Hyperoxaluria, nephrolithiasis in cystic fibrosis and, 1-11
- Hyperparathyroid and mixed bone disease, K/DOQI Clinical Practice Guidelines, S3:123-124
- Hyperparathyroidism, secondary
bone remodeling changes after parathyroidectomy, 729-738
in chronic kidney disease, S3:29-44
in postmenopausal HD patients, pamidronate effects on PTH secretion, 1221-1227
renal HD patients, percutaneous ethanol injection therapy for, 739-745
- Hyperphosphatemia
in chronic kidney disease, S3:29-44
in end-stage renal disease, lanthanum carbonate for, 96-107
- Hypertension
aortic atherosclerosis in chronic renal failure, 277-285
chronic kidney disease risk and, S4:34-S4:41
health status of elderly, cystatin C and, 36-43
KEEP program patients, S4:16-27
in pregnancy, cardiovascular disease and thromboembolic events associated with, 982-989
progression of renal insufficiency in type 2 diabetes mellitus, 936-942
state of endothelium in HD patients, circulating endothelial cells and, 704-712
targeted kidney disease screening and, 22-35
treatment in incident HD and peritoneal dialysis, 1260-1269
- Hyperuricosuria, nephrolithiasis in cystic fibrosis and, 1-11
- Hypoalbuminemia
chronic kidney disease and, 256-263
inflammation and oxidative stress in maintenance HD patients and, 286-294
- Hypocalcemia, in chronic kidney disease, S3:29-44
- Hypochloremia, after small bowel transplant rejection-related diarrhea, 1283-1286
- Hypocitraturia, nephrolithiasis in cystic fibrosis and, 1-11
- Hypoglycemia, gabapentin-induced, in long-term peritoneal dialysis patient, 6:E24
- Hypomagnesemia, in atypical Gitelman's syndrome, 6:E26
- Hypotension, anterior ischemic optic neuropathy in children on chronic peritoneal dialysis, 5:E19
- Hypovolemia, anterior ischemic optic neuropathy in children on chronic peritoneal dialysis, 5:E19
- Idiopathic membranoproliferative glomerulonephritis, clinical course, VEGF excretion and, 1139-1148
- IgA1, produced by tonsillar lymphocytes in IgA nephropathy, 486-496
- IL-4 gene polymorphisms, in children with minimal change nephrotic syndrome, 271-276
- Imaging. *See also specific imaging methods*
of medullary cystic kidney disease with MRI, 1:E2
nephrology core curriculum, 601-604
- Immune complex syndromes, hepatitis C virus and, 631-657
- Immunoglobulin A nephropathy
nuclear factor κ -B detection in, 76-86
resistin blood level increase in glomerulonephritis, 62-66
tonsillar lymphocytes IgA1 O-glycan structure in, 486-496
- Immunosuppression
sirolimus-induced thrombotic microangiopathy after renal transplant, 202-206
thrombotic microangiopathy after renal transplantation and, 1058-1068
- Inflammation
albumin and creatinine independent association with, 1200-1211
chronic kidney disease and, 256-263
erythropoietin hyporesponsiveness in maintenance HD and, 761-773
in maintenance HD patients with hypoalbuminemia, 286-294
markers in ESRD hemodialysis patients, 1212-1220
serum markers. *See also* C-reactive protein; Interleukin-6
chronic kidney disease and, 256-263
and muscle mass in long-term hemodialysis, 295-302
urinary albumin in type 2 diabetes and, 53-61
- Inherited kidney diseases, nephrology core curriculum, 1305-1317
- Insulin resistance
in renal disease, resistin and, 62-66
rosiglitazone in nondiabetic uremic patients on CAPD, 774-780
- Intact parathyroid hormone, bone management in quotidian hemodialysis, S1:24-29
- Interferon- α
in HCV-positive hemodialysis patients, 143-150
for hepatitis C virus-related renal disease, 631-657
- Interleukin-1, in ESRD hemodialysis patients, 1212-1220
- Interleukin-6
effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance HD, 761-773
in ESRD hemodialysis patients, 1212-1220
in maintenance HD patients with hypoalbuminemia, 286-294
muscle mass in long-term hemodialysis and, 295-302
- Interstitial nephritis, Tamm-Horsfall glycoprotein and, 658-676
- Interventional nephrology program
development of, 229-233
peritoneoscopic PD catheter insertion, bowel perforation from, 1270-1274
as work in progress, 388-391

- Intradialytic weight gain, quotidian hemodialysis and, S1:13-17
- Intravascular lymphoma, diagnosed by percutaneous kidney biopsy, 960-971
- In vitro closure time test, for hemostasis assessment in HD patients, 746-751
- Iothalamate clearance, prediction of GFR in liver transplant candidates, 1169-1176
- Iron
dialysis membrane composition effect on erythrocyte response, 551-560
heme iron polypeptide in HD patients, 325-330
- Ischemic renal injury, atherosclerotic renal artery stenosis and, 858-863
- Japanese patients
with minimal change nephrotic syndrome, IL-4-related gene polymorphisms in, 271-276
with type 2 diabetes, erythrocyte aldose reductase in, 943-951
- Kaplan-Meier survival curves, vs. Charlson Comorbidity Index for predicting survival in ESRD, 125-132
- K/DOQI Clinical Practice Guidelines
adynamic bone disease, S3:125-127
aluminum overload and toxicity in CKD, S3:108-116
background, S3:29-44
bone disease in kidney transplant recipient, S3:130-143
chronic kidney disease
for dietary phosphorus restrictions, S3:63-70
phosphate binder usage, S3:70-77
clinical performance measures based on, 806-812
definition of chronic kidney disease, 623-625, 626-630
dialysate calcium concentrations, S3:98-102
evaluation of calcium and phosphorus metabolism in chronic kidney disease, S3:52-57
hyperparathyroid and mixed bone disease, S3:123-124
metabolic acidosis, S3:129-130
methods for analysis of literature, S3:45-51
 β 2-microglobulin amyloidosis, S3:102-108
osteomalacia, S3:124-125
parathyroidectomy in CKD, S3:127-129
phosphorus evaluation in chronic kidney disease, S3:62-63
statements, S3:12-28
targeted kidney disease screening and, 22-35
treatment algorithm for aluminum overload, S3:116-122
vitamin D insufficiency/deficiency treatment, S3:84-89
Vitamin D therapy in dialysis patients, S3:92-98
work group members, biographical sketches, S3:144-147
- KEEP program
analytical methods, S4:57-60
anemia and chronic kidney disease, S4:49-S4:56
demographics, S4:8-15
early detection of kidney disease in community setting, 22-35
overview, S4:3-15
patient characteristics, S4:16-27
- Ketoacidosis, caused by starvation and stress, 5:E22
- Kidney, donor allocation, 882-890
- Kidney Disease Outcomes Quality Initiative. *See* K/DOQI Clinical Practice Guidelines
- Kidney Early Evaluation Program. *See* KEEP program
- Kidney function
effects of analgesic usage in healthy men, 234-244
levels, in predicting seroconversion after HBV immunization, 1184-1192
- Kidney stones, cystic fibrosis and, 1-11
- Kidney transplantation
access, late referral to nephrologist and, 1043-1049
allograft. *See* Allograft, renal
for amyloidosis, long-term outcome of, 370-375
cadaveric, de novo systemic lupus erythematosus after, 3:E15
correction of hypercoagulability in end-stage renal disease, 797-805
donor kidney allocation, 882-890
for ESRD, S5:115-128
evaluation, timing of, 1050-1057
in Finland, cost analysis of, 1228-1238
HBV- and HCV-infected allograft, evaluation of, 193-201
for HCV-positive patients, long-term ribavirin therapy for, 184-192
for hepatitis C virus-related renal disease, 631-657
hereditary papillary renal cell carcinoma in renal allograft, 381-384
impact of referral on ESRD outcome, 474-485
preemptive
residual renal function effects on graft and patient survival rates, 1275-1282
vs. nonpreemptive, 1050-1057
quality of life after, 431-445
recipients
bone disease in, S3:130-143
coronary risk factors, exercise training effects on, 362-369
sirolimus-induced thrombotic microangiopathy in, 202-206
recurrence of ANCA-positive glomerulonephritis after, 4:E18
retransplantation after polyoma BK virus-associated allograft loss, 821-825
Korean man, *NCCT* gene mutations in atypical Gitelman's syndrome, 6:E26
- Kt/V, quotidian hemodialysis and, S1:42-48
- Laboratory survey, of microalbuminuria testing methods, 245-248
- Lacrimal secretion, in end-stage renal disease, 722-728
- Lactate dehydrogenase, effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance HD, 761-773
- Lamellar osteoid, after parathyroidectomy for secondary hyperparathyroidism, 729-738
- Lanthanum carbonate, safety/efficacy of, 96-107
- Large-artery derangement, extracellular fluid-to-intracellular fluid volume ratio and, 990-999
- LCDD. *See* Light chain deposition disease
- LDH, effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance HD, 761-773

- LDL apheresis, for steroid-resistant focal segmental glomerulosclerosis, 1121-1130
- Lead-time bias, residual renal function in preemptive kidney transplantation and, 1275-1282
- Legal aspects, of stem cell therapy for renal disease, 891-905
- Leptin, in dialysis renal osteodystrophy, 1036-1042
- Leukocytosis, chronic kidney disease and, 256-263
- Levofloxacin, pharmacokinetics in ESRD, 342-349
- LHCDD, monoclonal gammopathy deposition and, 87-95
- LIFE (Losartan Intervention for Endpoint reduction), anti-hypertensive usage to reduce cardiovascular risk in dialysis patients, 1301-1304
- Light and heavy chain deposition disease (LHCDD), monoclonal gammopathy deposition and, 87-95
- Light chain amyloidosis, monoclonal gammopathy deposition and, 87-95
- Light chain cast nephropathy, monoclonal gammopathy deposition and, 87-95
- Light chain deposition disease (LCDD)
monoclonal gammopathy deposition and, 87-95
with renal involvement, 1154-1163
- Linkage analysis, in Alport's syndrome and benign familial hematuria, 952-959
- Lipids, aortic atherosclerosis in chronic renal failure, 277-285
- Lipoprotein(a)
atherosclerotic cardiovascular disease in dialysis patients and, 108-116
carotid atherosclerosis in PD patients and, 355-361
- Lipoprotein glomerulopathy, with psoriasis vulgaris, with apolipoprotein E3/3, 3:E14
- Liposomal amphotericin B, for mucormycosis peritonitis during long-term peritoneal dialysis, 3:E13
- Liver enzymes, evaluation of HBV- and HCV-infected renal allografts, 193-201
- Liver fibrosis
evaluation of HBV- and HCV-infected renal allografts, 193-201
HCV-positive renal transplant patients, long-term ribavirin therapy for, 184-192
- Liver histology, HCV-positive renal transplant patients, long-term ribavirin therapy for, 184-192
- London Daily/Nocturnal Hemodialysis Study, patient monitoring in, S1:61-65
- Losartan Intervention for Endpoint reduction (LIFE), anti-hypertensive usage to reduce cardiovascular risk in dialysis patients, 1301-1304
- Low-density lipoprotein apheresis, for steroid-resistant focal segmental glomerulosclerosis, 1121-1130
- Lymphomas, diagnosed by percutaneous kidney biopsy, 960-971
- Magnetic resonance imaging, of medullary cystic kidney disease, 1:E2
- Maintenance hemodialysis
in ESRD, hypercoagulability and, 797-805
hypoalbuminemia linked with inflammation and oxidative stress in, 286-294
- Malacoplakia, positron emission tomography of, 3:E17
- Malnutrition
of CAPD patients, long-term study of amino acid dialysate in, 173-183
with inflammation in dialysis, 864-881
in long-term hemodialysis, inflammatory mediators and, 295-302
peritoneal membrane abnormalities and, 787-796
- Malnutrition-inflammation complex syndrome
in dialysis, 864-881
effect on EPO hyporesponsiveness in maintenance HD, 761-773
- Mass screening methods, for microalbuminuria testing, 245-248
- Matrix metalloproteinase 9 gene, in ESRD, 133-142
- MDRD. *See* Modification of Diet in Renal Disease
- Medical education
core nephrology curriculum. *See* Nephrology core curriculum
need for end-of-life care training in nephrology, 813-820
- Medical Outcomes Survey 36-Item Short Form, quality of life on quotidian hemodialysis, S1:36-41
- Medullary cystic kidney disease
magnetic resonance imaging of, 1:E2
nephrology core curriculum, 1305-1317
type 2, Tamm-Horsfall glycoprotein and, 658-676
- MELD (Model for End-Stage Liver Disease), prediction of GFR in liver transplant candidates, 1169-1176
- Membranoproliferative glomerulonephritis (MPGN)
clinical course, VEGF excretion and, 1139-1148
dense deposit disease
early renal allograft dysfunction and, 207-211
retinal abnormalities causing visual impairment, 2:E3
hepatitis C virus and, 631-657
hygiene hypothesis of, 575-581
type I, renal dysfunction prognosis, α -smooth muscle actin and, 1131-1138
type II, early renal allograft dysfunction and, 207-211
- Membranous glomerulopathy
with collapsing glomerulopathy in native kidney biopsies, 591-595
dual pattern of immunofluorescence positivity, 419-426
- Men
carotid atherosclerosis in PD patients and, 355-361
chronic kidney disease risk and, S4:34-S4:41
quality of life in ESRD and, 713-721
- Mesangial proliferative glomerulonephritis
hygiene hypothesis of, 575-581
nuclear factor κ -B expression in, 76-86
- Mesangiocapillary glomerulonephritis type II, retinal abnormalities causing visual impairment, 2:E3
- Metabolic acidosis, K/DOQI Clinical Practice Guidelines, S3:129-130
- Metabolic alkalosis, hypochloremic, after small bowel transplant rejection-related diarrhea, 1283-1286
- Metalloproteinase inhibitor, proteinuria in crescentic glomerulonephritis and, 366-380
- MGUS (monoclonal gammopathy of undetermined significance), renal disease and, 87-95
- Microalbuminuria
all-cause mortality and, 466-473
as cardiovascular risk marker, 596-598

- current testing methods, 245–248
- prediction in diabetes mellitus, urinary albumin to osmolality ratio and, 685–692
- progression of renal insufficiency in type 2 diabetes, 936–942
- targeted kidney disease screening and, 22–35
- in type 2 diabetes mellitus, 53–61
- Microangiopathy, sirolimus-induced thrombotic, after renal transplant, 202–206
- β 2-Microglobulin amyloidosis, K/DOQI Clinical Practice Guidelines, S3:102–108
- Microscopic polyangiitis, subarachnoid hemorrhages in, 582–585
- Minimal change nephrotic syndrome
 - in children, 271–276, 1107–1113
 - IL-4-related gene polymorphisms in, 271–276
 - mycophenolate mofetil and prednisolone for, 1114–1120
 - nuclear factor κ -B expression in, 76–86
- Minocycline, ANCA-positive crescentic glomerulonephritis and, E9
- Model for End-Stage Liver Disease (MELD), prediction of GFR in liver transplant candidates, 1169–1176
- Modification of Diet in Renal Disease (MDRD)
 - C-reactive protein in chronic kidney disease and, 44–52
 - prediction of GFR in liver transplant candidates, 1169–1176
- Monitoring of patient, during daily and nocturnal hemodialysis, S1:61–65
- Monoclonal gammopathy
 - with nephrotic syndrome, 1097–1101
 - renal disease and, 87–95
- Monoclonal light chain deposition, intracellular accumulation, 605–611
- Montana, microalbuminuria testing in, 245–248
- Morbidity in ESRD, USRDS annual report on, S5:103–114
- Mortality
 - AVF creation by nephrologists and, 1293–1300
 - dialysis access type in ESRD patients and, 1013–1019
 - hypertension treatment in incident HD and peritoneal dialysis, 1260–1269
 - microalbuminuria and, 466–473
 - from renal artery stent placement, predictive value of renal insufficiency in, 926–935
- MPGN. *See* Membranoproliferative glomerulonephritis
- Mucormycosis peritonitis, on long-term PD, liposomal amphotericin B for, 3:E13
- Multorgan failure, during sickle cell crisis in sickle/ β +thalassemia, E4
- Multiple myeloma, with crystals in podocytes, 605–611
- Multiple organ failure, single-dose ofloxacin pharmacokinetics in CVVH, 310–314
- Multivariate analysis, of health status in elderly, 36–43
- Muscle mass
 - creatinine and albumin levels in dialysis patients and, 1200–1211
 - in long-term hemodialysis, inflammatory mediators and, 295–302
- Muscular paralysis, Sjogren's syndrome with Gitelman's syndrome and, 586–590
- Mutations
 - in Alport's syndrome and benign familial hematuria, 952–959
 - Na-CL cotransporter gene in Gitelman's syndrome, 6:E26
- Mycophenolate mofetil, with prednisolone for steroid-dependent nephrotic syndrome, 1114–1120
- Myeloma, with focal segmental glomerulosclerosis, 1097–1101
- Myeloma nephropathy, Tamm-Horsfall glycoprotein and, 658–676
- Myocardial infarction, hypertensive pregnancy and, 982–989
- Na⁺/H⁺ exchanger isoform 3 protein (NHE3), as marker for tubular injury in ARF, 497–506
- Narcotic analgesics, in end-stage renal disease, 217–228
- National Health and Nutrition Examination Surveys (NHANES)
 - second
 - inflammatory markers, CKD and, 256–263
 - receipt of RRT, sociodemographic disparities in, 249–255
 - third
 - chronic kidney disease risk, S4:34–S4:41
 - demographics of KEEP program, S4:8–15
 - KEEP program participant characteristics, S4:16–27
- National Kidney Disease Education Program, early detection of chronic kidney disease, 392–393
- National Kidney Foundation Kidney Early Evaluation Program. *See also* KEEP program
 - annual data report, S4:5–60
- Natural immunity, HBV, in long-term HD patients, 1193–1199
- NCCT gene mutations, in Korean Gitelman's syndrome patient, 6:E26
- Neonate, nephrotic syndrome in, 1318–1323
- Nephrin, in congenital nephrotic syndrome, 1318–1323
- Nephrocalcinosis, in cystic fibrosis, 1–11
- Nephrolithiasis, cystic fibrosis and, 1–11
- Nephrologists, AVF creation, 1293–1300
- Nephrology, need for end-of-life care training in, 813–820
- Nephrology core curriculum
 - cystic and inherited kidney diseases, 1305–1317
 - imaging, 601–604
 - as outline for nephrology trainees, 215–216, 395–418
 - for peritoneal dialysis, 1082–1096
 - renal biopsy, 826–836
- Nephropathy, nondiabetic, effect of ACE inhibitors on, 67–75
- Nephrosclerosis, progression of renal insufficiency in type 2 diabetes mellitus, 936–942
- Nephrotic syndrome
 - HIV-associated, in African-American male, 6:E25
 - with monoclonal gammopathy, 1097–1101
 - non-minimal change, in children, 1107–1113
 - in renal lymphoma, diagnosis by percutaneous kidney biopsy, 960–971
- NHANES. *See* National Health and Nutrition Examination Surveys
- NHE3 protein, as novel urinary markers for early ARF, 599–600

- NKF-K/DOQI Clinical Practice Guidelines. *See* K/DOQI Clinical Practice Guidelines
- Nocturnal hemodialysis
- adequacy of, S1:42-48
 - anemia management, S1:18-23
 - calcium and phosphate balance in, S1:24-29
 - London Daily/Nocturnal Hemodialysis Study, S1:5-12
 - nursing issues, S1:56-60
 - nutritional status and, S1:30-35
 - operating cost comparisons for, S1:49-55
 - patient monitoring, S1:61-65
 - patient quality of life, S1:36-41
 - technical considerations, S1:66-70
 - volume control and blood pressure management in, S1:13-17
- Nondiabetic patients with microalbuminuria, all-cause mortality and, 466-473
- Nonhypertensive patients with microalbuminuria, all-cause mortality and, 466-473
- Nonproliferative glomerulonephritis, nuclear factor κ -B expression in, 76-86
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- in end-stage renal disease, 217-228
 - renal disease in postphenacetin era and, 385-387
- Nord-Trøndelag Health Study (HUNT), microalbuminuria, all-cause mortality and, 466-473
- Normocarb replacement fluid, and citrate anticoagulation for pediatric CVVH, 1248-1252
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
- Nuclear factor κ -B, detection in IgA nephropathy, 76-86
- Nursing issues, in quotidian hemodialysis, S1:56-60
- Nutrient protein equivalent of total nitrogen appearance, quotidian hemodialysis and, S1:30-35
- Nutritional, long-term study in CAPD, 173-183
- Nutrition
- albumin and creatinine independent association with, 1200-1211
 - dietary glycotoxins, circulating AGEs in renal failure and, 532-538
 - quotidian hemodialysis and, S1:30-35
- Obesity
- chronic kidney disease risk and, S4:34-S4:41
 - KEEP program participants, S4:16-S4:27, S4:28-S4:33
- Ofloxacin, pharmacokinetics during CVVH, 310-314
- O-Glycan structure, of IgA1 produced by tonsillar lymphocytes in IgA nephropathy, 486-496
- On-line hemodialysis, reduction of advanced glycation end products in long-term HD, 524-531
- Operating costs, comparison of conventional vs. home quotidian hemodialysis, S1:49-55
- Opioids, for pain in hemodialysis, 1239-1247
- Organ allocation, for kidney transplantation, 882-890
- Osteoblasts, after parathyroidectomy for secondary hyperparathyroidism, 729-738
- Osteoclasts, after parathyroidectomy for secondary hyperparathyroidism, 729-738
- Osteomalacia, K/DOQI Clinical Practice Guidelines, S3:124-125
- Osteoporosis, intestinal calcium absorption in hypercalciuric stone-forming women and, 1177-1183
- Osteoprotegerin
- progression of vascular calcification in long-term HD and, 303-309
 - serum leptin in renal osteodystrophy and, 1036-1042
- Outcome
- conversion from conventional to daily HD for ESRD patients, 1020-1035
 - dialysis costs in ESRD and, 12-21
 - of dialysis with malnutrition-inflammation complex, 864-881
 - ESRD, USRDS annual report on, S5:103-114
 - long-term of kidney transplantation for amyloidosis, 370-375
 - of severe acute respiratory syndrome in dialysis, 1075-1081
- Oxalate nephropathy
- nephrolithiasis in cystic fibrosis, 1-11
 - rapidly progressive renal failure with pancreatic insufficiency, 842-845
- Oxalobacter formigenes*, nephrolithiasis in cystic fibrosis and, 1-11
- Oxaluria, nephrolithiasis in cystic fibrosis and, 1-11
- Oxidative stress
- during hemodialysis, ascorbic acid effects on, 158-166
 - in maintenance HD patients with hypoalbuminemia, 286-294
- Pain
- in hemodialysis patients, 1239-1247
 - quality of life in ESRD and, 713-721
- Pamidronate, PTH secretion in postmenopausal HD patients with secondary hyperparathyroidism, 1221-1227
- Pancreas transplantation, quality of life after, 431-445
- Pancreatic function
- insufficient, with rapidly progressive renal failure, 842-845
 - in peritoneal dialysis patients, 787-796
- Parathyroidectomy
- in CKD, K/DOQI Clinical Practice Guidelines, S3:127-129
 - for secondary hyperparathyroidism, bone remodeling changes after, 729-738
 - vs. percutaneous ethanol injection therapy for renal hyperparathyroidism in HD patients, 739-745
- Parathyroid hormone (PTH). *See also* Hyperparathyroidism
- lanthanum carbonate effects on, 96-107
 - secretion, pamidronate effects in postmenopausal HD patients with secondary hyperparathyroidism, 1221-1227
 - serum leptin in renal osteodystrophy and, 1036-1042
- Patient education, time to dialysis and, 693-703
- PD. *See* Peritoneal dialysis
- Pediatric patients. *See* Children
- Peginterferon, pharmacokinetics in ESRD, 631-657
- Pentoxifylline, urinary NAG in type 2 diabetes and, 264-270
- Percutaneous angioplasty, of atherosclerotic renal artery stenosis, 851-857, 858-863
- Percutaneous ethanol injection therapy, for HD patients with renal hyperparathyroidism, 739-745

- Percutaneous renal artery angioplasty, for atherosclerotic renal artery stenosis, 851-857
- Peritoneal dialysis (PD). *See also specific peritoneal dialysis modalities*
- adequacy of, 1082-1096
 - adult, ESRD Clinical Performance Measures Project 2002 Annual Report on, S2:39-48
 - anatomic findings in, 1082-1096
 - carotid atherosclerosis, factors associated with, 355-361
 - complications, peritoneal-mediastinal leakage, 2:E7
 - core curriculum, 1082-1096
 - culture-negative peritonitis, clinical course in, 567-574
 - in diagnostic and interventional nephrology program, 229-233
 - gastrointestinal and pancreatic function in, 787-796
 - hypertension treatment in, 1260-1269
 - long-term
 - amino acid dialysate in, 173-183
 - gabapentin-induced hypoglycemia in, 6:E24
 - for mucormycosis peritonitis, liposomal amphotericin B for, 3:E13
 - peritonitis, depression and, 350-354
 - outcome, impact of referral in ESRD, 474-485
 - peritoneoscopic catheter insertion, bowel perforation from, 1270-1274
 - ultrafiltration volume, measurement by segmental bioimpedance analysis, 167-172
- Peritoneal equilibrium test, in nephrology core curriculum, 1082-1096
- Peritoneal-mediastinal leakage, as peritoneal dialysis complication, 2:E7
- Peritoneal membrane
- abnormalities, malnutrition and, 787-796
 - anatomy of, 1082-1096
 - function in uremia, ENOS gene polymorphisms and, 781-786
- Peritoneoscopy, for PD catheter insertion, bowel perforation from, 1270-1274
- Peritonitis
- culture-negative, clinical course in peritoneal dialysis, 567-574
 - in long-term peritoneal dialysis, depression and, 350-354
 - mucormycosis, long-term PD and liposomal amphotericin B for, 3:E13
- P-glycoprotein, hepatic drug metabolism in kidney disease and, 906-925
- Pharmacokinetics
- of drugs in kidney disease, 906-925
 - of levofloxacin in ESRD, 342-349
 - single-dose ofloxacin in CVVH, 310-314
- Phosphate, quotidian hemodialysis and, S1:24-29
- Phosphate binders
- in chronic kidney disease, K/DOQI Clinical Practice Guidelines, S3:70-77
 - lanthanum carbonate, safety/efficacy of, 96-107
- Phosphorus, serum
- assessment in chronic kidney disease, S3:62-63
 - lanthanum carbonate effects on, 96-107
 - metabolism evaluation, S3:52-57
- PKD (polycystic kidney disease), autosomal recessive and dominant, 1305-1317
- Plasma cell dyscrasia, with focal segmental glomerulosclerosis, 1097-1101
- Plasmapheresis, for diffuse alveolar hemorrhage in small-vessel vasculitis, 1149-1153
- Platelet aggregation test, vs. in vitro closure time test for hemostasis assessment in HD patients, 746-751
- Platelet glycoprotein receptor inhibitors, for acute coronary syndromes in renal patients, 446-455
- Pneumonia, severe acute respiratory syndrome in hemodialysis patient, 1069-1074
- Podocin, in congenital nephrotic syndrome, 1318-1323
- Podocytes
- in congenital nephrotic syndrome, 1318-1323
 - crystals in, 605-611
 - vascular endothelial growth factor expression, in MGN, 1139-1148
- Polyarteritis nodosa, subarachnoid hemorrhages in, 582-585
- Polycystic kidney disease (PKD), autosomal recessive and dominant, 1305-1317
- Polymerase chain reaction (PCR), evaluation of HBV- and HCV-infected renal allografts, 193-201
- Polymorphisms
- C-106T of *AKR1B1*, in diabetic nephropathy, 943-951
 - matrix metalloproteinase 9 gene, in ESRD, 133-142
- Polyoma BK virus-associated interstitial nephritis, allograft loss, retransplantation after, 821-825
- Polysulfone capillary hemofilter, single-dose ofloxacin pharmacokinetics and, 310-314
- Positron emission tomography, of renal malacoplakia, 3:E17
- Poverty, receipt of renal replacement therapy and, 249-255
- Predialysis psychoeducational intervention, time to dialysis and, 693-703
- Prednisolone with mycophenolate mofetil, for steroid-dependent nephrotic syndrome, 1114-1120
- Prednisone, with LDL apheresis, for steroid-resistant focal segmental glomerulosclerosis, 1121-1130
- Preeclampsia, hypertensive pregnancy and, 982-989
- Preemptive renal transplantation
- residual renal function effects on graft and patient survival rates, 1275-1282
 - vs. nonpreemptive renal transplantation, 1050-1057
- Preexisting crescentic glomerulonephritis, in renal allograft, 5:E23
- Pregnancy, hypertensive, cardiovascular disease and thromboembolic events associated with, 982-989
- Prognosis
- cardiac markers in ESRD, 513-523
 - in light chain deposition disease with renal involvement, 1154-1163
 - of MPGN type I renal dysfunction, α -smooth muscle actin and, 1131-1138
- Program to Improve Care in Acute Renal Disease (PICARD), reasons for nonenrollment in, 507-512
- Progression
- of atherosclerotic renal artery stenosis, medical management of, 851-857
 - of IgA nephropathy, nuclear factor κ -B and, 76-86
 - of renal insufficiency in type 2 diabetes, 936-942

- Protein-energy malnutrition
 erythropoietin hyporesponsiveness in maintenance HD and, 761-773
 with inflammation in dialysis, 864-881
- Protein kinase C β inhibition, for diabetic nephropathy with vascular complications, 456-465
- Protein-losing enteropathy, in peritoneal dialysis patients, 787-796
- Protein turnover, in ESRD hemodialysis patients, 1212-1220
- Proteinuria
 in crescentic glomerulonephritis, doxycycline effects on, 376-380
 in nondiabetic nephropathy, effect of verapamil vs. amlodipine for, 67-75
 position statement of NKF and NIDDK, 617-622
 prognosis for LCDD with renal involvement, 1154-1163
 progression of renal insufficiency in type 2 diabetes mellitus, 936-942
 urinary NAG excretion in type 2 diabetes, pentoxifylline effects on, 264-270
 VEGF excretion in idiopathic MGN, 1139-1148
- Proteolysis, in ESRD hemodialysis patients, 1212-1220
- Psoriasis vulgaris, with protein glomerulopathy and apolipoprotein E3/3, 3:E14
- Psychosocial factors, quality of life in ESRD and, 713-721
- PTH. *See* Parathyroid hormone
- Pyuria, targeted kidney disease screening and, 22-35
- Quality improvement, clinical performance measures based on K/DOQI Clinical Practice Guidelines, 806-812
- Quality of life
 after kidney and pancreas transplantation, 431-445
 in ESRD, S5:151-160
 ↓
 conversion from conventional to daily HD, 1020-1035
 symptoms, spiritual beliefs, psychosocial factors and ethnicity, 713-721
 pain in hemodialysis and, 1239-1247
 on quotidian hemodialysis, S1:36-41
- Quotidian hemodialysis
 adequacy of, S1:42-48
 anemia management, S1:18-23
 calcium and phosphate balance in, S1:24-29
 conventional vs. home, cost comparison of, S1:49-55
 equipment and water treatment considerations, S1:66-70
 nursing issues, S1:56-60
 nutritional status and, S1:30-35
 patient quality of life, S1:36-41
 volume control and blood pressure management in, S1:13-17
- Race
 chronic kidney disease risk and, S4:34-S4:41
 quality of life in ESRD and, 713-721
- Randomized controlled trials. *See specific randomized controlled trials*
 of ARF, reasons for nonenrollment in, 507-512
 Cochrane Renal Group report on, 837-841
- Recombinant human erythropoietin (rHuEPC)
 hemodialysis membrane composition effect on erythrocyte response, 551-560
 hyporesponsiveness in maintenance HD, malnutrition-inflammation complex syndrome and, 761-773
- Recurrence of ANCA-positive glomerulonephritis, after kidney transplantation, 4:E18
- Reference values, for microalbuminuria testing, 245-248
- Referrals
 impact on outcomes in ESRD, 474-485
 late, access to kidney transplantation and, 1043-1049
- Regeneration, stem cell therapy for renal disease, 891-905
- Rehabilitation, ESRD, S5:151-160
- Religion, quality of life in ESRD and, 713-721
- Renal artery stenosis
 atherosclerosis, medical management of, 851-857, 858-863
 stent placement, predictive value of renal insufficiency in, 926-935
- Renal biopsy
 of congenital nephrotic syndrome, 1318-1323
 evaluation of HBV- and HCV-infected renal allografts, 193-201
 nephrology core curriculum, 826-836
 non-minimal change nephrotic syndrome in children, 1107-1113
 percutaneous, for lymphoma diagnosis, 960-971
 preexisting crescentic glomerulonephritis in renal allograft, 5:E23
 ultrasound guided in diagnostic and interventional nephrology program, 229-233
- Renal cell carcinoma, multicentric papillary, in renal allograft, 381-384
- Renal failure/insufficiency. *See also* Acute renal failure; Chronic kidney disease
 with acute coronary syndromes, antithrombotic agents for, 446-455
 circulating AGEs, dietary glycotoxins and, 532-538
 clinical course of culture-negative peritonitis complicating PD, 567-574
 in light chain deposition disease, 1154-1163
 predictive value of renal artery stent placement, 926-935
 rapidly progressive, with pancreatic insufficiency, 842-845
 stem cell therapy for, 891-905
 in vitro closure time test for hemostasis assessment in, 746-751
- Renal hyperparathyroidism, percutaneous ethanol injection therapy effectiveness in HD patients, 739-745
- Renal lymphoma, diagnosed by percutaneous kidney biopsy, 960-971
- Renal malacoplakia, positron emission tomography of, 3:E17
- Renal osteodystrophy, in HD patients, serum leptin in, 1036-1042
- Renal replacement therapy. *See also specific renal replacement therapies*
 in Finland, cost analysis of, 1228-1238
 predialysis psychoeducational interventions, time to dialysis and, 693-703
 single-dose ofloxacin pharmacokinetics in, 310-314
 for type 1 diabetes, incidence of ESRD and survival after, 117-124
- Renal stem cells, for kidney disease, 891-905

- Renal transplantation. *See* Kidney transplantation
- Renal tubular dysfunction, in β -thalassemia minor, 1164–1168
- Renal tubular regeneration, by bone marrow-derived cells after BMT, 5:E20
- Renal ultrasonography, for diagnostic and interventional nephrology program, 229–233
- Renovascular hypertension, atherosclerotic renal artery stenosis and, 858–863
- Residual renal function, graft and patient survival rates in preemptive renal transplant patients, 1275–1282
- Resistin, insulin resistance in renal disease and, 62–66
- Restenosis, access blood flow monitoring methods and, 539–545
- Retinal abnormalities, in mesangiocapillary glomerulonephritis type II, 2:E3
- Retrograde pyelography, acute renal failure after, 2:E6
- Revascularization, of atherosclerotic renal artery stenosis, 851–857, 858–863
- Reverse epidemiology, malnutrition-inflammation complex syndrome in dialysis and, 864–881
- rHuEPO. *See* Recombinant human erythropoietin
- Ribavirin
for hepatitis C virus-related renal disease, 631–657
long-term therapy for HCV-positive renal transplant patients, 184–192
- Risk adjustment, adapting Charlson Comorbidity Index for ESRD, 125–132
- Risk factors
for aortic atherosclerosis, in chronic renal failure, 277–285
for chronic kidney disease, KEEP program participants and, S4:34–S4:41
- Rosiglitazone, glucose metabolism in nondiabetic uremic patients on CAPD and, 774–780
- Ruboxistaurin, for diabetic nephropathy with vascular complications, 456–465
- Salivary secretion, in end-stage renal disease, 722–728
- Sacroileitis, adult-onset tubulointerstitial nephritis and uveitis and, 3:E11
- SARS. *See* Severe acute respiratory syndrome
- Saxon's test, in long-term dialysis patient with ESRD, 722–728
- Screening, targeted for early kidney disease evaluation, 22–35
- Segmental bioimpedance analysis, of ultrafiltration volume in peritoneal dialysis, 167–172
- Selection bias, reasons for nonenrollment in ARF cohort study, 507–512
- Seroconversion of HBV, stage of chronic kidney disease and, 1184–1192
- Sevelamer, and calcium acetate, bioavailability of ciprofloxacin and, 1253–1259
- Severe acute respiratory syndrome (SARS)
in dialysis patients, clinical presentation and outcome of, 1075–1081
in hemodialysis patient, 1069–1074
- Severity of illness, adapting Charlson Comorbidity Index for ESRD, 125–132
- Shirmer's test, in long-term dialysis patient with ESRD, 722–728
- Sickle cell disease, multiorgan failure during sickle cell crisis in sickle/ β -thalassemia, E4
- Signal transduction inhibition, for diabetic nephropathy with vascular complications, 456–465
- Sirolimus-induced thrombotic microangiopathy, in renal transplant recipient, 202–206, 1058–1068
- Sjogren's syndrome, with Gitelman's syndrome presenting with muscular paralysis, 586–590
- Skin bleeding time, vs. in vitro closure time test for hemostasis assessment in HD patients, 746–751
- SLE. *See* Systemic lupus erythematosus
- Small bowel transplant, rejection-related diarrhea, hypochloremic metabolic alkalosis from, 1283–1286
- Small-vessel vasculitis, diffuse alveolar hemorrhage, plasmapheresis for, 1149–1153
- Smoking, KEEP program patients, S4:16–27
- α -Smooth muscle actin, MPGN type I renal dysfunction prognosis and, 1131–1138
- Socioeconomic status
chronic kidney disease incidence and outcomes and, 677–684
dysregulation of immune balance resulting in glomerulonephritis, 575–581
receipt of renal replacement therapy and, 249–255
- Sodium-chloride cotransporter, Gitelman's syndrome with Sjogren's syndrome, 586–590
- Sodium fractional excretion, renal tubular dysfunction in β -thalassemia minor, 1164–1168
- Southwestern histochemistry, detection of nuclear factor κ -B in IgA nephropathy, 76–86
- Specimen handling, for microalbuminuria testing, 245–248
- Spirituality, quality of life in ESRD and, 713–721
- Starvation, severe acidosis caused by, 5:E22
- STAT6 gene polymorphisms, in children with minimal change nephrotic syndrome, 271–276
- Steal syndrome, transposed basilic vein arteriovenous fistula and, 151–157
- Stem cell therapy
autologous transplantation, for LCDD with renal involvement, 1154–1163
for renal disease, 891–905
- Stenosis
detection in AVFs, ultrasound dilution blood flow rate for, 331–341
renal artery
atherosclerosis, medical management of, 851–857, 858–863
stent placement, predictive value of renal insufficiency in, 926–935
restenosis, access blood flow monitoring methods and, 539–545
in vivo validation of glucose pump test for access flow, 752–760
- Steroid resistance
in focal segmental glomerulosclerosis, prednisone and LDL apheresis for, 1121–1130
in minimal change nephrotic syndrome, tacrolimus for, 5:E21
- Stone disease, Tamm-Horsfall glycoprotein and, 658–676

- Stress**
 oxidative
 during hemodialysis, ascorbic acid effects on, 158–166
 in maintenance HD patients with hypoalbuminemia, 286–294
 severe acidosis caused by, 5:E22
- Stroke, hypertensive pregnancy and, 982–989**
- Strontium absorption test, intestinal calcium absorption in hypercalciuric stone-forming women and, 1177–1183**
- Subarachnoid hemorrhages, in vasculitis, 582–585**
- Surgical technique, in predicting successful AVF maturation, 1000–1012**
- Surveillance, access, in vivo validation of glucose pump test for access flow, 752–760**
- Survival**
 in ESRD, Charlson Comorbidity Index prediction of, 125–132
 light chain deposition disease with renal involvement, 1154–1163
 residual renal function in preemptive kidney transplantation and, 1275–1282
- Symptoms, quality of life in ESRD and, 713–721**
- Systemic lupus erythematosus**
 de novo after cadaveric renal transplantation, 3:E15
 hemodialysis patient with ESRD and SARS, 1069–1074
- Tacrolimus**
 in steroid- and cyclophosphamide-resistant MCNS, 5:E21
 thrombotic microangiopathy after renal transplantation and, 1058–1068
- Tamm-Horsfall glycoprotein**
 biology and clinical relevance, 658–676
 uromodulin gene mutations, renal manifestations of, E8
- Terminal illness, analgesia in end-stage renal disease, 217–228**
- Thalassemia, multiorgan failure during sickle cell crisis in sickle/β+ thalassemia, E4**
- β-Thalassemia minor, renal tubular dysfunction in, 1164–1168**
- T helper cell subsets, hygiene and socioeconomic dysregulation, glomerulonephritis development and, 575–581**
- Thiazide, for Gitelman's syndrome with Sjogren's syndrome, 586–590**
- Thin basement membrane disease, nephrology core curriculum, 1305–1317**
- Thromboembolism, hypertensive pregnancy and, 982–989**
- Thrombolytics, for acute coronary syndromes in renal patients, 446–455**
- Thrombosis, prediction in AVFs, ultrasound dilution blood flow rate for, 331–341**
- Thrombotic microangioplasty, after renal transplantation, 1058–1068**
- Thrombotic thrombocytopenic purpura, thrombotic microangiopathy after renal transplantation and, 1058–1068**
- Time to dialysis, predialysis psychoeducational intervention and coping styles, 693–703**
- Time trade-off, quality of life on quotidian hemodialysis, S1:36–41**
- Tonsillar lymphocytes, IGA1, O-glycan structure in IgA nephropathy, 486–496**
- Training, nurse, in quotidian hemodialysis, S1:56–60**
- Tramadol, in end-stage renal disease, 217–228**
- Trandolapril, with verapamil vs. amlodipine in nondiabetic nephropathy, 67–75**
- Transesophageal echocardiography, of aortic atherosclerosis in CRF, 277–285**
- Transposed basilic vein arteriovenous fistula, vascular access outcomes, 151–157**
- Triple-lumen catheters, vs. dual-lumen catheters for hemodialysis and apheresis, 315–324**
- Tropins, prognostic value in ESRD, 513–523**
- Tuberous sclerosis complex, nephrology core curriculum, 1305–1317**
- Tubulointerstitial injury, urinary NAG excretion in type 2 diabetes, pentoxifylline effects on, 264–270**
- Tubulointerstitial nephritis**
 Gitelman's syndrome with Sjogren's syndrome, 586–590
 Tamm-Horsfall glycoprotein and, 658–676
 and uveitis, associated with sacroileitis and EBV infection, 3:E11
- Tumor necrosis factor-α**
 effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance HD, 761–773
 in ESRD hemodialysis patients, 1212–1220
 in peritoneal dialysis patients, 787–796
 urinary albumin excretion in type 2 diabetes mellitus and, 53–61
- Ubiquitin, in ESRD hemodialysis patients, 1212–1220**
- Ubiquitin-proteasome pathway, hemodialysis effects on, 1212–1220**
- Ultrafiltration volume measurement, by segmental bioimpedance analysis, 167–172**
- Ultrasonography**
 for diagnostic and interventional nephrology program, 229–233
 dilution method
 access blood flow in AVFs, 331–341
 vs. color Doppler ultrasound or fistulography, 539–545
- United States Renal Data System (USRDS)**
 analytic methods, S5:182–213
 2003 annual data report, S5:4–224
 chronic kidney disease, S5:37–46
- ESRD**
 cardiovascular special studies, S5:141–150
 clinical indicators and preventive care, S5:87–102
 economic costs, S5:161–172
 incidence and prevalence, S5:47–60
 international comparisons, S5:173–181
 outcomes, S5:103–114
 patient characteristics, S5:61–74
 pediatric, S5:129–140
 program overview, S5:13–24
 rehabilitation and quality of life, S5:151–160
 transplantation, S5:115–128
 treatment modalities, S5:75–86
- Healthy People 2010, S5:25–36**
- services, S5:214–223**

- thrombotic microangiopathy after renal transplantation and, 1058-1068
- UNOS Point System, for cadaver kidney allocation, 882-890
- URAT1* gene, exercise-induced ARF with familial renal hypouricemia, 1287-1292
- Urea filtration rate/volume, quotidian hemodialysis and, S1:42-48
- Urea kinetics, quotidian hemodialysis and, S1:42-48
- Uremia
- dialysis membrane composition effect on erythrocyte response, 551-560
 - nondiabetic, rosiglitazone effect on insulin resistance in CAPD, 774-780
 - pamidronate for in postmenopausal HD patients with secondary hyperparathyroidism, 1221-1227
 - resistin blood levels in, 62-66
- Urinary biomarker, for tubular injury in ARF, 497-506
- Urinary calculi, in cystic fibrosis, 1-11
- Urinary proteins, Tamm-Horsfall glycoprotein, 658-676
- Urine volume, nephrolithiasis in cystic fibrosis and, 1-11
- Urolithiasis
- in cystic fibrosis, 1-11
 - Tamm-Horsfall glycoprotein and, 658-676
- Uromodulin
- gene mutations, renal manifestations of, 2:E8
 - Tamm-Horsfall glycoprotein and, 658-676
- USRDS. *See* United States Renal Data System
- Vascular access. *See also specific vascular access methods*
- blood flow monitoring
 - by ultrasound dilution blood method, for AVFs, 331-341
 - ultrasound dilution vs. color Doppler ultrasound or fistulography, 539-545
 - in vivo validation of glucose pump test for, 752-760 - conversion from conventional hemodialysis to daily hemodialysis for ESRD patients, 1020-1035
 - in London Daily/Nocturnal Hemodialysis Study, S1:5-12
 - outcome, transposed basilic vein arteriovenous fistula and, 151-157
 - patency, transposed basilic vein arteriovenous fistula and, 151-157
 - predictors of successful AVF maturation, 1000-1012
 - in quotidian hemodialysis, S1:56-60
 - recirculation, ultrasound dilution blood method for AVFs, 331-341
- Vascular calcification, in long-term HD, serum osteoprotegerin and, 303-309
- Vascular disease, progression of renal insufficiency in type 2 diabetes mellitus, 936-942
- Vascular endothelial growth factor, urinary excretion, MGN clinical course and, 1139-1148
- Vasculitis
- with glomerulonephritis, effects of doxycycline on, 366-380
 - subarachnoid hemorrhages in, 582-585
- Verapamil, with trandolapril, proteinuria in nondiabetic nephropathy and, 67-75
- Viral replication, HBV and HCV in renal allograft, evaluation of, 193-201
- Visual impairment, in mesangiocapillary glomerulonephritis type II, 2:E3
- Vitamin C, effect on oxidative stress parameters in HD, 158-166
- Vitamin D
- insufficiency/deficiency, treatment of, S3:84-89
 - metabolic alterations in CKD, S3:29-44
 - therapy
 - for CKD patients, S3:89-92
 - for dialysis patients, S3:92-98
- Water treatment, for quotidian hemodialysis, S1:66-70
- White blood cell count, chronic kidney disease and, 256-263
- Women
- chronic kidney disease risk and, S4:34-S4:41
 - hypercalciuric stone-forming, intestinal calcium absorption and BMD in, 1177-1183
 - postmenopausal, pamidronate for secondary hyperparathyroidism in, 1221-1227
 - quality of life in ESRD and, 713-721
 - thrombotic microangiopathy after renal transplantation and, 1058-1068
- Xerophthalmia, in end-stage renal disease, 722-728
- Xerostomia, in end-stage renal disease, 722-728
- Zinc excretion, renal tubular dysfunction in β -thalassemia minor, 1164-1168